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Biotherapeutic products are lifesaving medicines for cancer, autoimmune and 
infectious diseases. In the last few years, the pharmaceutical industry has seen a 
massive spike in the development of biologics – over 2,700 biologics in development 
reported in 2018 alone. This trend fuels an ever-growing need for the development of 
new analytical methodologies to characterize the structure and function of 
biopharmaceutical products. The application of such new methodologies advances the 
understanding of their degradation mechanisms and provides useful knowledge in 
designing and meeting regulatory criteria. 
An overview of biopharmaceutical peptides, mAbs and biosimilars available on 
the market, along with their currently published analytical characterizations and typical 
instability mechanisms, are summarized in the first chapter. In the second chapter, we 
investigated the long-term stability of exenatide, a 39 amino acid GLP-1 receptor 
agonist peptide used to treat type 2 diabetes, under different experimental conditions. 
When exenatide was incubated at an elevated pH, rapid chemical and physical 
degradation occurred. Chemical degradation was characterized by a pH-dependent 
increase of deamidation impurities while physical degradation was mainly attributed to 
dimerization, aggregation and loss of α-helicity. The addition of excipients such as 
sucrose, mannitol and sorbitol showed a slight reduction of monomer loss at pH 7.5. 
In the third chapter, a comparability study between originator and biosimilar 
infliximab (Remicade® and Remsima™) was performed. Forced degradation was 
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implemented to understand whether initial minor analytical differences could be 
amplified over the course of incubation. Some minor differences were found over 
incubation, including differences of heat capacity, intrinsic fluorescence, subvisible 
particulates, deamidation tendencies and fragmentation levels. Differences were not 
determined to be statistically significant and degradation mechanisms and kinetics were 
found to be highly similar. 
In the fourth chapter, a tandem mass-spectrometry method was employed to 
detect, identify and quantify disulfide bonds and related impurities (shuffled disulfide and 
trisulfide bonds) in originator and biosimilar pars of infliximab, rituximab and 
bevacizumab. Infliximab and bevacizumab biosimilars had higher levels of shuffled and 
trisulfide bonds relative to the originators, while rituximab biosimilar and originator had 
the similar levels of impurities. The bevacizumab and rituximab pairs were than 
incubated for 4 weeks at 37ºC to examine the kinetics of physical degradation by size 
exclusion chromatography and electrophoresis gels and disulfide shuffling by tandem 
mass-spectrometry. The two mAb pairs responded differently to forced degradation. 
The rituximab biosimilar had a slightly higher initial level of aggregation over incubation, 
relative to the originator, though degradation products were low and not exacerbated 
over the 4-week incubation. In contrast, the bevacizumab biosimilar had higher initial 
levels of protein aggregates and shuffled disulfide bonds, relative to the originator 
product, but also had exacerbated extent of aggregation and disulfide shuffling over the 
incubation than rituximab. This study indicates that originator and biosimilar pairs 
respond differently to forced degradation and that tandem mass-spectrometry is a 
useful tool to track the formation of covalent aggregates. 
 xvii 
Taken altogether, the thesis highlights the importance of the combination of 
classical analytical methodologies with new mass-spectrometry techniques to 
characterize instability mechanisms for peptide and mAb products subjected to forced-
degradation conditions. The application of these techniques allows researchers, 
manufacturers and regulators to explore differences and similarities between reference 




Chapter 1: Introduction 
 Background and Significance of the Analytical Characterization of Biologics 
Biologic product development has been a growing field with a breadth of 
therapeutic applications including, but not limited to autoimmune, cancer, hematologic, 
and infectious diseases.1–4 The massive spike in the development of biologics (over 
2700 reported in 2018) has been fueled by improvements in the understanding and 
emphasis of biologic drug efficacy and safety. These improvements have been made 
possible by recent advancements in protein analytics technologies as well as by the 
development of regulatory pathways .5–8 Biologic products are large, complex molecules 
derived from living cells that include (but are not limited to) therapeutic recombinant 
proteins, vaccines and blood components.9 As shown in Fig. 1-1, small molecules like 
acetaminophen (151.2 Da) can be thought of as bicycles relative to small biologics (e.g. 
erythropoietin, 30kDa) and large biologics (e.g. IgG,150 kDa), respectively thought of as 
cars and airplanes.10 Biologics are not only more complex in structure but are also more 
complex in their manufacturing processes. Biologic manufacturing relies on dynamic 
and environmentally sensitive living cell systems, which can pose problems such as 
high molecular heterogeneity within batches; and high potential for elicitation of 
immunogenic response in patients.11–13 For these reasons, development of methods for 
the extensive analytical characterization of biologics has been deemed necessary. This 




biosimilars, generic biologics that have no clinically meaningful differences from a 
previously approved biologic.14 Extensive analytical characterization is required to 
ensure similarity of characteristics that could potentially lead to alteration of a biologic’s 
safety, purity and potency.15 
The phenomenon of developing extensive analytical characterization techniques 
has grown significantly since the approval and entry of the first biosimilar into the 
European market by the European Medical Association’s (EMA) in 2016.16 The EMA 
and U.S. Food and Drug Administration (FDA) have since together approved over 75  
 biosimilars.17,18 Many companies continue to design and submit new biosimilars for 
approval in hopes that a successful drug will gain entry into a market space worth over 
$80 billion in revenue as of 2020 for the top 10 mAb and mAb-like products alone (Table 
1-1). In order to reach regulatory approval, extensive characterization of biologics and 
biosimilars must first be conducted to ensure safety, efficacy and overall “similarity”.  
Figure 1-1. Molecular weight and complexity differences between small molecules, small biologics and 




Fig. 1-2 visually represents the differences in development processes between 
innovator biologics, biosimilars and generic small molecules. Small molecule generics 
are passed through the abbreviated new drug application (ANDA) process, where 
approval only requires proof of matching bioequivalence and bioavailability data in 
healthy subjects.10,19,20 On the other hand, biosimilar development focuses on extensive 
analytical characterization to ensure no differences in terms of clinical efficacy or safety 
when compared with its innovator counterpart. 21–27 Not only does this increase the time 
to market but also the number of steps and money required to develop biosimilars.  
Table 1-1. Top 10 selling mAb/mAb-related products, brands, indications and 2020 sales 




Analytical Characterization of Critical Quality Attributes 
Critical quality attributes (CQAs) are defined as the physical, chemical, biological, 
or microbiological properties that must be studied to ensure a desired product quality.28 
Certain CQAs must be characterized in order to claim biosimilarity. Analysis of CQAs for 
biosimilar products starts by selecting individual attributes, including molecular 
structure, mechanism of action, safety and efficacy and then defining appropriate 
analytical characterization methods for their analysis.29,30 Through various models, 
utilizing both quantitative and/or qualitative methods, each CQA is assessed for its 
relative criticality and the potential risk of impact on clinical outcomes (PK, PD, etc.).31 
 Examples of CQAs based on their criticality that are used for analytical 
biosimilarity assessment of an infliximab molecule are shown in Table 1-2 from high to 
low criticality.32,33 
Table 1-2. Examples of analytical biosimilarity assessment of infliximab CQAs, criticality and impacts. 




 CQAs are categorized into three tiers (Table 1-3).32–34 Tier 1 (high criticality) is 
assumed to impact biological activity, PK/PD, immunogenicity, and safety. Tier 2 
(moderate criticality) can potentially impact biological activity, PK/PD, immunogenicity, 
and safety, requiring a “quality range approach”, where values must fall within a 
specified number of standard deviations from a mean (depending on the assessment). 
Tier 3 (low criticality) is assumed to have little to no impact on biological activity, PK/PD, 
immunogenicity and safety and are typically assigned and assessed both comparatively 
and qualitatively.30,35 The FDA has not officially determined a preferred approach for 
analysis of CQAs or the determination of criticality. Their previously draft guidance 
document on “statistical approaches to evaluate analytical similarity” was withdrawn due 
to unforeseen complexities.31,36–38 In contrast, the EMA does not require tier assignment 
for analytical assessments nor a specific subsequent statistical analysis method but is 
currently, in conjunction with the FDA, discussing ways to improve and define the 
analytical assessment of biosimilarity definitions.32 Examples of CQAs of analytical 
relevance that require characterization include amino acid sequences, disulfide bonds, 
carbohydrate attachments, molecular weights, extinction coefficients, and 
electrophoretic, liquid chromatographic, and spectroscopic patterns.33,39  
Table 1-3. The 3-tiered approach for biosimilar statistical quality attribute evaluation. EM: equivalence 




 Forced Degradation Studies as a Tool to Characterize Biopharmaceuticals 
 Forced degradation studies have been used to support the drug development 
process and to evaluate manufacturability through the application of various stress 
conditions that include (but are not limited to) thermal (elevated temperature, 
freeze/thaw thermocycling), light (UV, daylight), chemical (low/high pH, metal-catalyzed 
oxidation) and physical (agitation) stresses.40,41 The objectives of these studies are to: 
(1) determine degradation pathways, (2) develop formulations, (3) develop analytical 
methods, (4) determine shelf-life, (5) mimic shipping and storage conditions (6) evaluate 
manufacturability, (7) assess CQAs and (8) determine intrinsic stability.42 Forced 
degradation through the use of stress conditions has recently been implemented during 
biosimilar comparability studies. Examples of such can be found in the literature and in 
Biologic License Application submissions, where analytical methods are used to assess 
degradation and the formation of impurities, such as those shown in  Table 1-4.10,43–47  
  




Significance of Forced Degradation Conditions 
The most common method of forced degradation is through the application of a 
thermal stress that exceeds typical and recommended storage conditions. These 
typically include storage at room temperature, 25°C, and temperatures above 35°C, and 
are commonly referred to as accelerated stability studies as specified in ICH 
guidelines.48 MAb products stressed at elevated temperatures for a shortened period of 
time above the typical storage temperature (2-8°C) can facilitate the formation of 
degradant impurities. High humidity may also be introduced in addition to thermal stress 
for drug substances stored in a solid form, including lyophilized mAbs.49,50 Freeze-thaw 
is another form of thermal stress often utilized for forced degradation studies for drug 
substances that may be exposed to multiple temperature transitions. An example 
biologic is insulin analog delivery devices that contain up to a month’s supply of 
injections that are potentially exposed to multiple transition temperatures as products 
are stored in the refrigerator but may be brought to room temperature multiple times 
during consumer handling. Freeze thaw studies also come in handy to determine the 
appropriate use of protective and stabilizing excipients in lyophilized drug products.51 
The major degradation pathway for freeze-thaw is aggregation, though precipitation and 
particle formation have been observed. To prevent this degradation, certain excipients 
can be added into the final product.52,53  
Biopharmaceuticals can also encounter physical (mechanical) stresses such as 
agitation, stirring or shaking during manufacturing, shipping and patient handling. 
Stirring, shaking, vortexing and sonication are all mechanical stresses commonly used 




stress can be found applied in combination with thermal stress, both sharing a major 
degradation pathway of aggregation. It should be noted that the underlying mechanisms 
of impurity formation may not only differ between one stress condition and the next, but 
also between two different molecules.59  
Another stress condition category called chemical stresses may occur when drug 
substances such as mAbs are exposed to low or high pH conditions during purification. 
Low pH can lead to aggregation and fragmentation that can be further exacerbated by 
the high concentration typical of mAb products, resulting in precipitation.60 High pH is 
known to drive asparagine deamidation and disulfide bond shuffling, also resulting in 
aggregation and fragmentation.61 Another chemical stress that can occur during the 
manufacturing of biologics is oxidation caused by dissolved oxygen and/or metal and 
surfactant impurity-derived free radicals.59 Hydrogen peroxide and tert-butyl hydrogen 
peroxide, in combination with or without zinc and copper metal ions, are the most widely 
used forced degradation reagents to test for oxidation.62 Peracetic acid (PAA) has been 
studied as an alternative oxidizing agent that specifically oxidizes methionine but not 
tryptophan63. Probing oxidation susceptible residues by forced oxidation is important 
since oxidation of site-specific residues (mainly methionine) can result in decreased 
drug potency when located at the site of antigen binding, or oxidation-induced 
conformational changes in the Fc domain that can lead to aggregation.60 
 Chemical and Physical Stability of mAb Therapeutics 
Chemical Stability 
Over the course of their lifetime, mAb biologics are subject to both enzymatic and 




physical stability and the formation of related impurities. These modifications are further 
separated into two categories. The first category is that of product variants, 
modifications that occur during the cell culture, extraction, and purification of the 
manufacturing process while the second category is that of product-related impurities, 
modifications that occur from storage onwards.64,65 Both categories of modifications can 
affect the final products’ stability, safety, and immunogenicity, and thus necessitate 
investigation. By applying the previously mentioned extensive analytical characterization 
techniques, abundant modifications including (but not limited to) amino acid 
modifications, charge variants and glycosylations can be identified and correlated with 
their potential to impede the approval of a final product.66–69  
The most commonly seen chemical impurities are those that form as a result of 
the modification of amino acids, including oxidation, deamidation and disulfide shuffling. 
Many of these impurities can also be classified as charge variants as modification of 
amino acids lead to changes of a molecules’ surface properties such as charge and 
hydrophobicity.70,71 Oxidation is a major chemical impurity induced by a reactive oxygen 
species (ROS) where an oxygen is inserted at an amino acid residue site. This mainly 
occurs at methionine residues though it has been observed at other amino acid 
residues including tryptophan, cysteine, histidine and lysine.72–77 When oxidation occurs 
at methionine, it  results in the formation of methionine sulfoxide (MetO) and, to a 
significantly lesser extent, the formation of an irreversible double oxidation impurity 
methionine sulfone (MetOO)(Fig. 1-3).78 Oxidation results in the disruption of the 
hydrophobic bond found in the aromatic side chains of some of the listed amino acid 




typically buried residues and increasing the number and type of surface exposed 
hydrophobic amino acid residues.79–82 
Deamidation is another major process leading to chemical impurity, described as 
the loss of an amide group that occurs mainly at asparagine (Asn) amino acid residues 
(as shown in Fig. 1-4) and at glutamine (Gln) amino acid residues. Asn deamidation in 
peptides and proteins has been shown to be highly pH and buffer dependent. In 
general, Asn deamidation is base-catalyzed, occurring between pH 5 and pH 8. Some 
common buffers including  phosphate, tris and carbonate buffers, exhibit increased 
deamidation propensity at pH greater than 7.83,84 Asn deamidation is known to form 3 
major impurities. The first is a succinimide intermediate that forms as a result of the loss 
of the amide group. The succinimide intermediate, which then racemizes into aspartic 
acid (Asp) and isoaspartic acid (Iso-Asp) impurities that are present in either the D or L 
conformation of Iso-Asp.85 Even at pH < 5, Asn deamidation can still occur through via a 
slightly different acid-driven mechanism. This phenomenon, where the succinimide and 
Asp impurities form at lower pH values and occur increasingly when followed by Serine 
(Ser) and Histidine (His) residues.83–92  
Figure 1-3. Methionine oxidation pathway that leads to the formation of methionine sulfoxide 




Gln deamidation has been shown to be barely detectable in biological products 
as a result of its approximately 100-fold slower rate of occurrence; nevertheless, it can 
still occur.86,87,93–97 N-terminal terminal pyroglutamic acid (PyroQ) formation (Fig. 1-5), 
also titled pyroE, pGlu and pyrELA, is a common chemical impurity that occurs as a 
result of removal of an amide group at N-terminal glutamine and glutamic acid amino 
acid residues. PyroQ formation has been observed in a variety of proteins, including 
mAbs and peptides both in solution and in the dry state.98–101 PyroQ formation 
generates acidic variants also through the loss of the positively charged primary 
amine.102,103Although we have mainly touched on pH dependence, deamidation relies 
on many other factors, including the primary structure of nearby amino acid residues, 
tertiary molecular structure, storage temperature, and formulation components (i.e. 
buffer strength and ionic strength).85,104,105 
Figure 1-4. Typical Asn deamidation pathway, proceeding through a succinimide intermediate, which 
undergoes isomerization, resulting in the formation of aspartic acid (Asp) and isoaspartic acid (isoAsp). 




Disulfide bond related impurities also fall into the chemical impurity category 
since they yield an amino acid modification. Disulfide bonding plays a critical role in the 
structure and function of proteins as its presence is necessary for the correct folding of 
proteins during translation and is responsible for stabilization.106,107 In IgGs, at least 12 
disulfide bonds are conserved. Disulfide bonds linking the light chain with heavy chains, 
called “inter-chain” disulfide bonds, are necessary to conserve quaternary structure, 
while bonds found within each sub-domain component, called “intra-chain” disulfide 
bonds, are necessary for stability.108 The heterogeneity of recombinant mAb disulfide 
bonding has been previously reported.102,109,110 Disulfide bond related impurities, 
including incorrect disulfide bonding, also known as disulfide shuffling, occurs when 
biologics are exposed to environmental stresses during downstream processing 
steps.111,112 Disulfide bonding is the exchange of a covalent bond location between the 
sulfur group of two cysteines and commonly occurs when the sulfur group of a free thiol 
attacks an existing disulfide bond, hence shuffling its location. Disulfide shuffling can 
occur either intra-molecularly, within a molecule, or inter-molecularly, between two 
molecules (Fig. 1-6). Free thiols and/or high pH conditions are implicated to be the main 
culprits of disulfide shuffling induction.113–116 Trisulfide bonding, whereby a third sulfur is 
inserted into an existing disulfide bond, is another chemical impurity that arises from the 
use of H2S during cell culture.117 It is a rare modification that is not currently implicated 






In summary, oxidation has been shown to induce the formation of aggregate 
impurities and the loss of function of various proteins. 59,120–125 For IgG1 and IgG2, 
several studies have reported that methionine (Met) oxidation in the Fc domain is 
related to weakened neonatal Fc receptor (FcRn) binding, which is a function related to 
IgG recycling and transcytosis.126 Due to the proximity of Met residues to the FcRn 
binding interface, oxidation can disrupt antibody conformation and the oligomerization of 
IgG, leading to decreased C1q binding and CDC activity.127–130 Deamidation is a main 
cause of chemical degradation and may introduce a local charge-related structure 
distortion.94,131 It has been reported that deamidation at the Asn30 location in the light 
chains of Herceptin® (the trastuzumab originator) showed a reduction of potency by 
70%, while deamidation at the Asn55 residue showed a 14-fold decrease in antigen 
binding affinity.94,97 Furthermore, Iso-Asp is a non-natural amino acid residue and 
deamidation induced impurity which means it is potentially immunogenic.132 It has been 
shown that the formation of pGlu impurities do not have significant clinical impact, but 
need to be monitored and identified as indicators of the introduction of heterogeneous 
species that may reflect a lack of manufacturing process control.133–136 One example of 
how modifications of disulfide bonds and the formation of related impurities impact 
Figure 1-6. Intra- and inter-molecular disulfide shuffling that occurs (A) between a free thiol and an 
existing disulfide bond within a molecule or (B) between two molecules. Here, free thiols are shown as 




molecular function has been evaluated in originator and biosimilar etanercept, an IgG-
like TNF-α inhibitor. Etanercept has a complex disulfide bonding pattern containing 29 
disulfide bridges throughout its structure. Various shuffled disulfide bond variants were 
investigated, whereby an increase of the percentage of samples with incorrect disulfide 
bonding at the 78-88 location were shown to be correlated with a potency loss (Fig. 1-
7).137–139  
Analytical characterization methods of chemical impurities are commonly liquid 
chromatography (LC) based and vary based on the desired impurities of interest. The 
most widely used analytical method for characterization of large proteins is digestion 
and analysis by LC-MS or MS/MS.94,140–143 These techniques have been implemented in 
comparability studies between innovator and biosimilar mAb pairs. Many additional 
methods have been used orthogonally as method-to-method variability has been 
observed for different techniques.144,145  
Other desired attributes of interest that result from chemical impurity formation 
include the formation of charge variants. These are commonly characterized by ion 
exchange chromatography (IEX), which separates proteins according to their overall net 
surface charge and can even differentiate isoforms that have single charge 
differences.43,44,46,47,146–149 To further identify the nature of each peak separated by IEX, 
Figure 1-7. (A) Correlation of % potency (TNF-α neutralization) with % incorrect disulfide bonding at 




subsequent orthogonal MS analysis is necessary. Proteins with high isoelectric points 
(pI), such as mAbs, are generally separated by cation exchange chromatography 
(CEX).147,150–152 Further details on mAb impurities differentiated by IEX can be found in 
the literature. CE-based methods in combination with MS can provide more rapid 
analyses leading to the use of small amounts of samples and reagents.153 
To characterize disulfide bonding for mAbs, analysis by RP-LC-MS/MS is 
currently regarded as the standard method. In this set of techniques, peptide fragments 
are generated using enzymatic digestion (such as trypsin) then separated by RP-LC 
and analyzed by MS/MS.154–156 This technique requires very low sample volume and 
outputs very large amounts of data, which requires the use of an analysis software that 
allows for the identification of disulfide bonds and their related impurities. As free thiols 
are implicated as the main factor for disulfide shuffling, the levels of surface exposed 
free thiols can be measured using Ellman’s reagent, assuming large amounts of free 
thiols present.44,157 Other techniques to analyze free thiols include the use of maleimide, 
which conjugates to free thiols and allows for analysis by RP-LC, as conjugated 
maleimide will form a more hydrophilic mAb species. Studies have been performed to 
optimize the combination of column conditions and maleimide reagents in order to 







The physical stability of mAbs, and therefore prevalent physical degradation 
pathways, are highly related to the formation of chemical impurities. As previously 
mentioned, chemical modifications can result in altered surface properties, including 
changes of charge and hydrophobicity. It is well understood that changes in surface 
properties are related to the formation of physical impurities, which include structural 
modifications and the formation of aggregate and fragment impurities. MAb aggregates 
fall under the category called higher order structures (HOS), which covers impurities 
ranging from  dimers to high molecular weight species.159 These differences in types of 
fragment and aggregate impurities can reflect the use of various forced degradation 
stress conditions as one condition may induce physical impurities differently than the 
next.59 Fig. 1-8 shows microscopy images of IgGs that were subjected to various stress 
conditions, where different types of aggregation were shown to occur under various 
stress conditions.160 These differences can also potentially reflect underlying changes of 
secondary, tertiary and quaternary structures that can be analytically characterized 
through the application of orthogonal methods.161 
Figure 1-8. Atomic Force Microscopy (AFM) images of IgG when subject to freeze-thaw, pH, heat, shake 




Another major challenge in producing biologics is their natural propensity to form 
complex aggregates.162 These aggregates vary in size (nm-μm), structure (native/non-
native), morphology (spherical/strand-like) aggregate type (fibrillar/amorphous) and 
reversibility.163 Not only does the presence of protein aggregates compromise 
therapeutic efficacy and bioavailability, it may also elicit immune responses to the 
protein drug that are measured by the formation of anti-drug antibodies (ADAs).164–168 
The elicited immune response can result from any combination of changes in solubility, 
viscosity  and exposure of neo-epitopes that cause a protein to be recognized as foreign 
by the immune system.165,169,170 In the case of the infliximab biosimilar, there have been 
reports that aggregates might affect TNF-α binding, which is a critical mechanism of 
action. Aggregates have also been linked to infliximab immunogenicity.43 However, 
there is no single method that can assess a wide size range of aggregates. Therefore, 
biosimilar developers should analyze aggregates by employing several orthogonal 
methods (Fig. 1-9) for cross-validation to ensure the presence of comparable or lower 
levels of aggregates with the reference throughout the product’s life cycle.  





Among the diverse methods of aggregate determination, size exclusion 
chromatography (SEC) is most commonly used for aggregate quantification and size 
estimation. SEC is based on the interaction of molecules with a column’s bead pores, 
which separates molecules from large to small depending on their size in solution.163 In 
addition, SEC can be combined with UV, fluorescence, multi-angle laser light scattering 
(MALS) and other detectors, though SEC-MALS is highly valuable, providing increased 
accuracy by acquiring absolute molar mass for each eluted fraction.171 However, it has 
been reported that SEC can incorrectly detect aggregates due to either unwanted 
secondary interactions with the stationary phase (adsorption), removal of large insoluble 
aggregates during sample preparation, or dissociation of reversible aggregates as a 
result of dilution.172–174 Further details of SEC and mAb aggregates can be found in the 
literature. Another alternative technique is asymmetric flow field-flow fraction (AF4), 
which determines particle size as a function of diffusion coefficient through the use of 
laminar and a perpendicular cross-flows across two different plates.175 AF4 can be 
combined with various detection methods such as UV, MALS and refractive-index.176 
However, method validation has been shown to be difficult.173  Analytical 
ultracentrifugation (AUC) is another commonly used method for size detection and can 
be utilized by sedimentation velocity (SV), a hydrodynamic approach, and 
sedimentation equilibrium (SE), a thermodynamic approach. In general, AUC separates 
particles of various shapes and sizes by centrifugal force and by detection with attached 
optical systems (absorbance/interference/fluorescence). The biggest advantage of AUC 




range of sample concentrations.177 While useful for absolute size measurements, AUC 
is low-throughput requiring high quality instrumentation and complicated analysis.163,178  
In terms of particle analysis, dynamic light scattering (DLS) and nanoparticle 
tracking analysis (NTA) are often used. Both techniques generate data as a function of 
particle diffusion coefficients based on Brownian motion and light scattering. DLS is a 
useful tool for quickly assessing size, providing a wider range of particle size and 
sample concentrations than NTA. DLS requires low sample volume (μL) where samples 
can be recollected for further analyses. DLS’s major limitation is that the reported 
intensity distribution of particle sizes is sensitive to the presence of large particle 
contaminants, which may dominate scattering signals and result in misrepresented 
particle size distributions.163,179,180 NTA tracks and visualizes movement of particles 
using a microscope coupled to a camera system and provides size distribution as a 
function of number distribution. Compared to DLS, NTA generates information on 
particle concentration in solution with a better resolution on samples with polydisperse 
size distribution. However, the reproducibility of NTA is low, often requires sample 
dilution for analysis, and is not useful for molecules that are too small, which constitutes 
several limiting factors when compared to DLS.179,181,182 
For the determination of secondary structure, Fourier transform infrared 
spectroscopy (FTIR), far-UV circular dichroism (CD), x-ray crystallography and nuclear 
magnetic resonance (NMR) are typically used, with FTIR and CD being most commonly 
employed.136,183–189 FTIR spectroscopy can be used regardless of the physical sample 
state with no limitation on protein size. It requires a relatively small amount of sample 




(10 ms).190,191 CD provides data in a relatively short time period with small amounts of 
sample (<20 µg), but requires aqueous samples. UV CD spectra are derived from the 
peptide bond region (<240 nm), therefore allowing conformational information to be 
obtained while secondary structure is estimated using various algorithms.73,74 These 
techniques are prevalent in literature for proteins that undergo changes of secondary 
structure such as the detection of β-fibrillation, a common physical impurity also formed 
in insulin and insulin analogs. Fig. 1-10 shows an example CD spectra for IgGs that 
were subjected to various stress conditions.160 NMR can be used to generate useful 
protein secondary structural data but requires high sample concentration and is time 
consuming. 1-D NMR is typically used more for smaller biopharmaceuticals and can be 
used as a fingerprint comparison to show the structural similarity between innovator and 
biosimilar products.139,193,194  
  
Figure 1-10. Far-UV CD spectra for GLP-1 subject to freeze-thaw, pH, heat, shake and oxidation stress. 




Applications of the following analytical techniques are shown in Fig. 1-11. 
Tertiary structure can be determined through near-UV CD, differential scanning 
calorimetry (DSC), 2D-NMR and mass spectrometry techniques such as hydrogen 
deuterium exchange (HDX-MS) and ion mobility (IM-MS). Near-UV CD (250-320 nm) 
can detect differences in the tertiary structural environment of disulfide bonds and highly 
environmentally sensitive aromatic residues.195–197 DSC is widely used to evaluate 
thermal and conformational stability during processing and manufacturing.198–200 Highly 
similar thermograms and Tms denote the similarity of tertiary structures as a result of 
thermal stability. Recently, 2D NMR has been utilized to provide sensitive, robust and 
precise structural assessment of biologics, but requires highly concentrated samples 
and long acquisition times.201 HDX-MS can monitor conformational protein dynamics, 
relying on the deuteration of labile hydrogen in amide bonds along the polypeptide 
backbone. These subtle HOS differences are detected by LC-MS analysis and 
quantified based on degrees and rates of deuterium exchange.54,55,64,97 The advantages 
of HDX-MS are its analytical capacities to measure exchange in complex buffer systems 
and large proteins, as well as its minimal sample requirement (5-100 pmol).203 IM-MS is 
a rapid (msec) and sensitive (nmol) emerging technique for generating HOS biologic 
fingerprints.204–207 In addition to IM-MS, collision induced unfolding (CIU) has been 
applied for structural analysis, yielding distinct protein unfolding patterns as a function of 
collisional heat, while resolving small variations in protein structures.204,208–210 Recently, 
CIUs were applied in an infliximab comparability study that showed comparable 





Impurities and Immunogenicity 
 Immunogenicity is the elicitation of an immune response by a patient to a 
therapeutic protein product. Immunogenic responses can range from no apparent 
clinical manifestations to life-threatening ones.213 Immunogenic response to the biologic 
erythropoietin is an example of a life-threatening immunogenic response whereby 
neutralizing anti-erythropoietin antibodies induce pure red-cell aplasia, resulting in fatal 
anemia.214 Currently, immunogenic responses are characterized by the formation of 









Figure 1-11. Methods that compare higher order structure of innovator/biosimilar infliximab. (A) far-UV 
CD. MRE: Molar Residue Ellipticity; RMP: Reference Medicinal Product.136 (B) DSC thermal overlay 
plot.136 (D) HDX-MS butterfly plots.202 (E) deuterium uptake difference plots.202 (F) IM-MS collision 
induced unfolding (CIU) fingerprints, showing averages (left) and Standard Deviations (right) of innovator 
(top) and biosimilar (bottom).211 Figures adapted with permission. 
Figure 1-12. Types of ADAs from “binding” to neutralizing to cross-reactive neutralizing, where frequency 




While long-term, adaptive immune response is the current focus for determining 
immunogenicity, the innate immune response has recently generated interest as well. 
People are studying the innate immune response  to determine initial immune response 
mechanisms that may then lead to downstream elicitation of an adaptive immune 
response.170 Fig. 1-13 shows the exposure of protein aggregates to an antigen 
presenting cell (APC), which can trigger immune responses through various kinds of 
pathways, including interactions with Fcγ, Toll-like and T-cell receptors. Following this 
interaction, the protein can then undergo receptor mediated phagocytosis, lysosomal 
digestion and presenting cell maturation.170,216  
APCs being studied for maturation in the literature mainly include dendritic cells 
and monocytes, though THP-1 is being used as a robust in vitro alternative that does 
not require derivatization from a human source.217  Following APC maturation, antigen 
peptide sequences can be investigated by the MHC associated peptide proteomics 
(MAPPs) assay, which allows for further elucidation of underlying immune response 
elicitation.218 Another common technique used to investigate immunogenicity is through 
Figure 1-13. In vitro interactions of protein aggregates with antigen presenting cells (APCs) that can 
potentially trigger an immune response through different kinds of receptors - FcγRs, TLRs and/or CRs. In 
addition, following receptor-mediated phagocytosis of aggregates, lysosome digested peptides are 






a whole blood assay, whereby a multiplex cytokine assay is used to determine cytokine 
responses in whole blood that has been taken from human patients.219 
As previously mentioned, various impurities have been suggested to be related 
to the elicitation of immunogenic response; though correlation between individual 
components and responses are highly complex and molecule dependent. 220  Several 
papers have been published investigating this relationship using forced degradation and 
the application of various stress conditions. It has been shown that different stress 
conditions applied to an IgG1 resulted in different cytokine responses, though it should 
be noted that these trends may not translate from one mAb to the next (Fig. 1-14).221 
Figure 1-14. Cytokine response profiles for IgG1subjected to thermal, pH, stir and syringe stress. Figure 




 Chemical and Physical Stability of Peptide Therapeutics 
Peptides are located in a unique space between small molecules and small 
biologics and can be thought of as mopeds relative to small molecules and large 
biologics (Fig. 1-15). Peptides can be manufactured synthetically, produced by 
recombinant technology, or purified from a biological source.222 Peptides generally 
serve as replacement therapies in cases of the dysregulation of the production or 
secretion of endogenous peptides and hormones. They have access to unique targets 
inaccessible by mAbs and small molecule products.223 The top 10 non-insulin peptide 
drug products are shown in Table 1-5. As peptides are composed of an underlying 
amino acid sequence, characterization of their chemical and physical stability is highly 
translatable from mAb characterization.  
Figure 1-15 Molecular weight and complexity differences between small molecules, 





Table 1-5. Top-10 marketed peptide products (2019) by brand, manufacturer, sales revenue, molecule class, synthetic/biologic nature, presence 




Like mAb products, oxidation and deamidation are also the most prevalent 
peptide chemical impurities.224,225 While the impact that chemical impurities have on 
mAb function depends on the location of the modification, the shortened sequence of 
peptides would imply that any chemical modification could significantly impact its 
function. In addition to the globular structure of proteins like IgG limits solvent 
accessibility because of imparted structural rigidity. Peptides, on the other hand, 
commonly lack quaternary structure and therefore steric hindrances, typically allowing 
for greater molecular flexibility. This flexibility makes them more susceptible to 
instability, as is the case for deamidation and oxidation chemical impurity formation in 
peptides.92,113,226–229 While this molecular flexibility can contribute to the presence of 
certain chemical degradation hotspots (i.e. NG amino acid combinations), such flexibility 
is also a consideration that must be accounted for when it comes to the conservation of 
receptor binding.222 As such, it is necessary to investigate a peptide’s chemical stability, 
including the formation of chemical impurities such as deamidation and oxidation, and 
its relationship with a peptide’s physical stability and function. Peptides, in comparison 
to large proteins that have highly defined quaternary structures, are generally 
understood to be more complex in nature and are known to have a distribution of 
conformational native states, sometimes in equilibrium between monomer, dimer and 
hexamer as is the case for native insulin.230 These native states are typically influenced 
by the secondary structure of each peptide that arises from the primary amino acid 
sequences. Shifts in secondary structure can arise from either one or a combination of 
α-helical, β-sheet and unordered secondary structural portions.  Chemical impurities 




complex physical impurities, including amorphous aggregation and β-sheet 
fibrillation.231,232 β-sheet fibrillation has been well studied in insulin and insulin analogs 
and is a well-known physical impurity formed in peptides.233 
 Deamidation has been determined as critical for insulin and insulin analogs.234 
Deamidation in peptides occurs as a result of many factors including pH, temperature, 
buffer species, ionic strength, structure and neighboring amino acid residues.87,235,236 
Asn followed by a glycine is a well-known deamidation hotspot in peptides and has 
been determined to undergo the most rapid rate of deamidation when compared to 
other peptide sequences.237 Deamidation of insulin has been shown to affect the tertiary 
structure via exposure of its hydrophobic core.238 Deamidation has also been shown to 
induce aggregation in the peptides such as amylin and β-B1-crystallin and has been 
established to correlate with bovine growth hormone aggregation.239–241 Oxidation in 
peptides has been shown to have mixed effects on aggregation, especially in terms of 
the type of aggregation that occurs (fibrillar or amorphous).242–244 PyroQ formation has 
been shown to occur at N-terminal glutamine and glutamic acid amino acid residues in 
peptides in both solution and solid states though its impact is complex and molecule-
dependent.99–101. Several peptides that are prone to PyroQ formation have been 
designed and modified to initially have pyroGlu substituted at these N-terminal 
locations. This design method is meant to prevent degradation and the potential loss of 
binding activity and efficacy.101 The complex nature of peptide aggregation has been 
shown for GLP-1, exhibiting the ability to form amorphous aggregates and β-sheet 
fibrils. These different aggregation types were formed as a result of many factors 




 While there are many analytical techniques that overlap between proteins and 
peptides for the determination of chemical and physical stability, the small nature of 
peptides does allow for the use of certain techniques that are not specified for larger 
proteins. Whereas large proteins like mAbs require digestion into small pieces for the 
analysis of chemical impurities, small peptides subject to analysis can be analyzed 
through direct application onto MS. LC interfaced with a time of flight (ToF) mass 
spectrometer allows for the identification of small mass changes that can be translated 
into amino acid modifications. Another commonly used technique for the detection and 
identification of physical impurities-aggregation or fragmentation is SEC. Aggregates 
can be further visualized with the use of microscopy techniques like TEM and by 
turbidity studies.233 In terms of the formation of physical impurities, secondary structure 
shifting is analyzed by CD. Since peptides are well known for their tertiary structures, 
the use of peptide absorbance techniques and tagging with fluorescent dyes have been 
implemented to detect various changes of structure. These techniques commonly 
include intrinsic fluorescence, whereby tertiary structure is detected through the solvent 
exposure of a tryptophan amino acid and thioflavin T (ThT), which binds to β-sheets and 
fluoresces to indicate β-fibrillation. Meanwhile, extrinsic fluorescent are of importance, 
such asanilinonaphthalene-8-sulfonic acid (ANS) that can bind to hydrophobic pockets 
that are commonly exposed with the breakdown of tertiary structure.233,246–248 Another 
technique often used for analysis of amyloid fibrillation for insulin and insulin analogs is 
Fourier transform IR spectroscopy.249 Other techniques such as HDX-MS have been 
used to investigate the amino acids responsible for the formation and interaction of β-




 Background: GLP-1 Receptor Agonists 
Glucagon like peptide-1 receptor agonists (GLP-1 RAs) are a class of peptide 
drug products that are used to treat type II diabetes mellitus patients that have 
developed an insulin resistance. These agonists were developed as safer, and more 
effective, glucose-dependent alternatives to previously used diabetes therapies, 
including metformin, insulins, sulfonylureas and thiazolidinediones, that have previously 
been associated with poor glucose homeostasis, weight gain and hypoglycemic 
events.251–253  
GLP-1 RAs are also known as mimetics of incretin, an endogenous hormone 
produced by intestinal enteroendocrine L-cells following nutrient ingestion, at high 
glucose levels.254 This class of therapies interacts with GLP-1 receptors (GLP-1Rs) that 
are located in various organs, including the pancreas, gastrointestinal tract, brain, heart 
and kidneys. Upon receptor binding, a multi-faceted physiological response is elicited 
that goes beyond the simple secretion of insulin.255,256 Physiological responses include 
activating the nervous system, decreasing body weight through the enhancement of 
satiety and energy uptake, slowing  gastric emptying, regulating glucagon secretion, 
and inducing β-cell proliferation and enhancing their resistance to apoptosis. The 
induction of apoptosis resistant β-cells is especially important as it has been 
hypothesized  to prevent further loss of endocrine pancreatic function.254,257–259 
Additionally, recent literature has delved into the neuroprotective application of GLP-1 




GLP-1 is impractical for therapeutic use itself as it rapidly degraded by the 
peptidase NEP 24.11 and by DPP4 at the Alanine 8 amino acid residue. This 
degradation means that in vivo GLP-1 only has a half-life of approximately 2.4 minutes. 
263 As part of the effort to design and develop therapies with improved longer half-lives, 
Alanine 8 is typically substituted in GLP-1 RAs.263 Not only does improving half-life allow 
for greater glucose control, but it also eases the use and improves the compliance for 
the administration of these therapies. The different GLP-1 RAs are shown in Fig. 1-16 
with the details of modification types and half-lives shown in Table 1-6.263 GLP-1 RAs 
include synthetically manufactured molecules exenatide and lixisenatide and molecules 
derived from a biologic source, including dulaglutide, liraglutide, albiglutide and 
semaglutide. 
Figure 1-16. Peptide sequences and molecular structures of FDA approved GLP-1RA, including GLP-1, 
exenatide, liraglutide, lixisenatide, semaglutide, dulaglutide and albiglutide. Yellow: key amino acids 
related to potency; Red: substituted amino acids; Blue: spacers; Green: IgG. Figure adapted with 




GLP-1Rs are part of the G-protein coupled receptor (GPCR) super ‘family B’, 
’secretin receptor-like family’ that includes receptors composed of an N-terminal domain 
of 100-150 residues connected to an integral membrane core domain that is typically 
GPCR-associated.264 GLP-1Rs, first cloned from rat pancreatic islets and then humans, 
show similarities to secretin, parathyroid hormone and calcitonin receptors.265–267 
Ligand-receptor binding has been proposed to occur through what is called the ‘two-
domain model’, where a ligand’s C-terminal helical region enables N-terminal interaction 
with the receptor’s core domain.264,268 Various GLP-1 like molecules, including several 
GLP-1 truncations, were studied in view of this “two-domain model”. These studies 
showed that the N-terminal residue was required to be a histidine in order to enable 
such interaction with the core domain. GLP-1 C-terminal variants that were truncated at 
the 6th/8th amino acid showed reduction of activity by approximately 300 fold, whereas 
cleavage of the single C-terminal residue only reduced activity up to 10 fold.269–271 
Micelle-forming lipids sodium dodecyl sulfate (SDS) and dodecyl phosphocholine (DPC) 




are commonly used to mimic membrane- or receptor-bound states, as most membrane 
binding peptides are unstructured in the monomeric solution state.272–275 Use of these 
micelle-forming lipids allows for GLP-1 variants to exist in a preferred, analysis friendly, 
conformational state .272–275 Altogether, these results show that modifications and 
conjugations must be designed with receptor binding in mind. Currently marketed GLP-
1 products are listed below in table 1-7 and includes several products that are co-




Table 1-7. GLP-1RA products, manufacturers, revenues (2019*), Y/Y % change, synthetic/biologic nature 




 Exenatide: An Approved GLP-1 Receptor Agonist 
Exenatide is a synthetic GLP-1 agonist that was initially derived from the venom 
of the Gila Monster (Heloderma Suspectum), a lizard that is native to the southwestern 
United States. Exenatide, also referred to as exendin-4 (Ex4), differs from exendin-3 
(Ex3) at two amino acid residues. Switching Ser2-Asp3 (Ex3) to  Gly2-Glu3 (Ex4) 
results in distinct bioactivities and greatly eliminates the vasodilation side effect 
exhibited in Ex3.276 Aside from amino acid switching, truncation of amino acids has also 
been studied in Ex4 and Ex3. It was found that truncation of the first 8 residues of Ex3 
yielded an antagonist, while similar truncation of the first two residues of Ex4 also 
rendered it an antagonist. Clearly, amino acid modifications of Ex3 and Ex4 are 
important and are worth further exploration, showing the importance and drastic effects 
of amino acid modifications.277–280 
Exenatide is the active pharmaceutical ingredient (API) found in AstraZeneca’s 
marketed product Byetta®, a solution formulation for twice-daily injection. Byetta® has 
since been superseded by the more successful Bydureon®, which contains exenatide 
encapsulated in poly(lactide-co-glycolic acid) (PLGA) microspheres for extended 
release, allowing it to be  injected weekly.281,282 Exenatide’s isoelectric point (pI) has 
been reported to be approximately 4.86 and, therefore, both Byetta® and Bydureon® are 
formulated at pH 4.5. Byetta® is formulated with mannitol and m-cresol excipients and is 
administered subcutaneously from a pen that contains a month’s worth of injections 
(60). Bydureon® microspheres are encapsulated with sucrose, where each pen contains 
a single dose containing a lyophilized powder (formulated with sucrose) that is 




ongoing research has been focusing on potential formulation approaches to develop 
exenatide into a monthly injection.263   
The amino acid sequence of exenatide is shown below with the locations of 
exenatide’s most likely chemical degradation sites highlighted in red, Asn28 followed by 
Gly29, a deamidation hotspot, as well as Met10 and Trp25, oxidation hotspots. Other 
potential chemical degradation sites include Asp (D) and Ser (S) hydrolysis and Gly (G), 




 The chemical stability of exenatide and the impact of its chemical impurities on 
GLP-1R has been previously studied in relation to a novel hydrogel technology, 
whereby exenatide was covalently attached to hydrogel microspheres.284 Exenatide was 
analyzed for the formation of chemical impurities after 8 (red), 28 (blue) and 56 days 
(green) of incubation at 37°C (Fig. 1-17).  
Figure 1-17 Chemical impurity formation of exenatide released from hydrogels over 56 days of incubation 





They found that major impurity for all time points was deamidation at Asn28, 
which appears at a retention volume of 10.8 mL.284 They showed that deamidation 
resulted in the formation of L-Asp, L-isoAsp and D-isoAsp impurities, which all showed 
decreased GLP-1R binding affinity in terms of increased EC50 relative to day 0.284 In 
attempt to avoid these deamidation impurities, the deamidation prone Asn28 was 
substituted with Gln28, where they were able to show reduced formation of the 
deamidation impurity while simultaneously maintaining similar activity and PK profiles to 
those seen without Asn28 modification.284 The lack of oxidation observed in this study 
implies that different formulation strategies can have different chemical instability 
pathways and tendencies when compared to exenatide alone in aqueous solution, 
where we observed similar trends for deamidation at pH 6.5 and above, although we 
observed the formation of oxidation impurities. 
Exenatide’s secondary structure is composed of the following: 1) an N-terminal 
strand from amino acids 1 - 8, with amino acids 1-6 being responsible for receptor 
binding; 2) an α-helical structure making up the majority of the structure from amino 
acids 9-27; 3) a C-terminal Trp cage that forms via the interaction between the side 
chains of Trp25 and the several proline residues (28 - 39).285 The α-helix has been 
suggested to be stabilized through salt bridging of positive and negative side chains and 
polar H-bonding, which can be disrupted by drastic changes of pH. The C-terminal Trp 
cage interaction has also been suggested to stabilize tertiary conformations of small 
proteins, hairpin peptides and peptide protein complexes.286–289 The physical stability of 
the Trp-cage miniprotein and other modified Trp-cage miniproteins have been 




approximately 42°C at pH 7, though in isolation. The cage was not found to interact with 
exenatide’s N-terminus, hence the reason it’s stability was investigated in isolation.290,291 
Concentration-dependent differences in secondary structure between exenatide 
samples at pH 4.4 were observed at 2°C for 2 (green), 40 (blue), 240 (red) and 600 μM 
(yellow) concentrations (Fig. 1-18). Similar trends were observed over CD melts at 
peptide concentrations that were between 2 (~0.0084 mg/mL) and 240 μM (1 mg/mL) 
when ramping from 10 to 90°C.285 It was concluded that exenatide is only monomeric 
with a partially formed Trp cage at concentrations < 10 μM., Samples at higher 
concentrations participate in aggregation via helix-helix interactions at residues 11-
26.285 The presence of helix-helix interactions and concentration dependence aligns 
with the general understanding that peptides can exist in multiple conformational states.  
In the presence of fluoro-alcohols,  exenatide has been shown to induce an 
increasingly helical tertiary structure with fully folded Trp-cage domains.285,292 This is 
contrary to the typical behavior of fluoro-alcohols, which entails β-sheet formation of 
Figure 1-18. Far-UV CD spectra of exenatide concentrations from 2 to 600 μM. Green: 2 μM; Purple: 40 




proteins to enhance stabilization through “solvophobic effects”.275,285,293 SDS and DPC 
micelles were used to investigate receptor binding and its effect on tertiary structure for 
a truncated 26-residue analog. It was observed that DPC micelle binding resulted in a 
loss of tertiary structure, likely attributed to the favorable interactions between Trp and 
the PC head groups. The Trp cage also showed SDS micelle binding, a phenomenon 
that has been previously reported in other Trp-containing peptides.272–274,287 While this 
does not elucidate the exact role of the Trp cage, it remains useful information for the 
design of receptor binding models. Several conformational isomers and their suggested 
role in aggregation are shown in Fig. 1-19. 
 
  
Figure 1-19. Potential conformational isomers and oligomeric species that could contribute to the solvent-
dependent equilibrium in exenatide at different concentrations as a function of Trp-cage unfolding. Figure 




 Infliximab: An Anti-TNF-α mAb 
There are a handful of biological products on the market that target TNF-α 
(commonly known as TNF-α inhibitors) to treat various autoimmune diseases, including 
rheumatoid arthritis (RA), psoriasis, ankylosing spondylitis, ulcerative colitis (UC) and 
Crohn’s disease (CD). Table 1-8 shows a list of products in the TNF-α inhibitor class, as 
well as their molecular name and type and whether a biosimilar version is available. 
While these molecules share overlapping mechanisms of action, there are a few 
important differences that must be identified in terms of molecule type, route of 
administration and potential for immunogenicity.  
  




 Amongst the listed anti TNF-α molecules, etanercept and infliximab stand out as 
outliers. Enbrel is a mAb-like biologic that is comprised of a TNF-α receptor 2 protein 
coupled to an IgG1-derived Fc domain. Without the Fab domain, etanercept lacks the 
ability to be approved for multiple inflammatory indications, such as Crohn’s and 
ulcerative colitis. Another difference between listed products is the route of 
administration. Infliximab products are administered intravenously by infusion while all 
other products are administered subcutaneously. This infusion is given over the course 
of 2 hours, which has been the preferred option for patients that consider fear of 
needles as the most influential factor of choosing a therapy. 
Additionally, molecules vary in their inherent potential for immunogenicity 
depending on their manufacturing source (cell lines). Chimeric molecules, which have 
mouse derived variable domains, have a higher immunogenicity potential compared to 
humanized and fully human molecules (Fig. 1-20).294 Infliximab is chimeric and 
certolizumab is humanized (mouse derived CDR) while adalimumab and golimumab are 
fully human.  
A review (Fig. 1-21) compared the immunogenic response for several of these 
molecules in patients with CD and UC.295 The authors observed that infliximab exhibited 
the greatest potential for immunogenic response compared to humanized and fully 
Figure 1-20 Sources of mAb manufacturing, including mouse derived, chimeric, humanized and human. 
Shown in the order of highest to lowest potential to elicit immunogenic response. Figure adapted with 




humanized molecules (though immunogenic responses were highly variable).295 It is 
generally understood that these molecules all have the potential to elicit an 
immunogenic response upon administration, but identification of key modulators 
resulting in immunogenicity remains complicated and full of confounding factors. 
Studies have been performed whereby the forced degradation of mAbs has shown that 
different stress types can lead to variations in immunogenic responses, thus affirming 
the complicated nature of studying and predicting immunogenicity.160  
 Despite the potential for immunogenicity, these TNF-α inhibitors are undeniably 
successful on the market. Due to their success, many companies have begun to create 
biosimilar versions of these drug products in hopes of outcompeting the innovator in the 
market once it has lost exclusivity. Changes in total sales revenues of the innovator and 
respective biosimilars have reflected this competition.  
Between 2016 and 2019 three infliximab biosimilars of Remicade® (Johnson & 
Johnson) were FDA approved, including Inflectra®/RemsimaTM (Celltrion), FDA 
approved in 2016, Fliaxabi®/Renflexis® (Samsung Bioepis), FDA approved in 2017, and 
AvsolaTM (Amgen), FDA approved in 2019. The total sales revenues of the innovator 
Remicade® have continued to fall since the approval of the first US approved infliximab 
biosimilar in 2016, decreasing from $6.97 Bn in 2016 to $4.4 Bn in 2019 (-36.9%).296 US 
Figure 1-21. Range of rates (%) of ADAbs formation to biologics in patients with IDBs. Only studies 
reporting rates of ADAbs were included, immunogenicity analyses are product- and assay-specific, 
infliximab excluded one study that had a small sample size (n = 28) and high rate of immunogenicity 
(79%). -: no publications available; ADAbs: anti-drug antibodies; CD: Crohn’s Disease; UC: Ulcerative 




sales revenues for Inflectra®/RemsimaTM (Celltrion) increased from $259 Mn in 2018 to 
$325 Mn in 2019 (+16%), while global sales of Renflexis®/Flixabi® (Samsung Bioepis) 
increased to $5.0 Bn in 2019 (+16.7% from 2018), with some contribution from US 
sales.297298299  2020 financial reports for some companies were unavailable. 
 As shown in Fig. 1-2, the major focus for the development of biosimilar mAbs is 
establishing analytical similarity to an innovator. This information can be found in 
regulatory filing documents and in published comparability studies. In both, various 
orthogonal analytical techniques are applied to establish similarity to the innovator 
product.43,144,211 Detailed analytical comparisons of the innovator, Remicade®, against 
biosimilar, Inflectra®/RemsimaTM, in literature and regulatory documents showed that 
there were minor differences found for levels of soluble aggregates, levels of basic 
charge variants and glycan distribution profiles.136,211,300 However, these differences are 
small enough that they were not considered to be a clinically relevant concern.  
When considering whether these minor differences are just that – minor – companies 
have to determine their potential impact on mAb function. The two main mechanisms of 
action for mAbs are TNF-α neutralization, via binding to soluble and membrane bound 
TNF-α, and ADCC, via FcγR3A binding. Therefore, assays such as TNF-α neutralization 
and FcγR binding are also implemented and required for regulatory approval. The 
FDA’s assessment report for Inflectra®/RemsimaTM compared TNF-α binding of  CT-P13 
against US and EU Remicade®  by ELISA (Fig. 1-22/23) and FcγR3A binding  to low (F) 
and high affinity (V) variants (Fig. 1-24/25). While TNF-α binding was similar, we do 
notice that there is a difference in terms of FcγR3A binding for both variants (differences 




al).301 The difference in binding is further understood by differences of glycan 
distribution profiles, which are also reported in this document (Fig. 1-26). Pisupati et al. 
performed a comparability study of these molecules (Fig. 1-27), utilizing LC-MS/MS to 
quantify glycan distribution and biolayer interferometry (BLI) to measure FcγR3A 
binding where similar results were reported; Remsima TM (CT-P13) showed fewer 
afucosylated glycans and a weaker FcγR3A binding affinity when compared with 
Remicade®.211 In the end, while minor analytical and functional differences have been 
found, they are generally assumed as of little importance as long as there are no 
clinically meaningful differences as defined by the FDA.14  
Figure 1-23. Results and Statistical Analysis of ELISA Binding of Transmembrane-Bound TNF-α. Dark 
Blue: CT-P13; Light Blue: ALAG CT-P13; Grey: EU Remicade; Yellow: US Remicade; ALAG: artificially 
elevated afucosylated glycans 
Figure 1-22. Results and Statistical Analysis of Binding of soluble TNF-α. Dark Blue: CT-P13; Light Blue: 









Figure 1-26. Scatter Plots Showing Relationship of % Afucosylated Glycan Species (G0 + Man 5) with 
FcγR3a Binding Affinity and ADCC Activity. Dark Blue: CT-P13; Grey: EU Remicade; Yellow: US 
Remicade. 
Figure 1-25. Quality Range Analysis of FcγRIIIa V variant binding by SPR. Dark Blue: CT-P13; Light Blue: 
ALAG CT-P13; Grey: EU Remicade; Yellow: US Remicade; ALAG: artificially elevated afucosylated 
glycans; Red: QR limits of variability. 
Figure 1-24. Quality Range Analysis of FcγRIIIa F variant binding by SPR. Dark Blue: CT-P13; Light Blue: 
ALAG CT-P13; Grey: EU Remicade; Yellow: US Remicade; ALAG: artificially elevated afucosylated 




 Analytically, biosimilars sufficiently match their innovator. However, there are still 
concerns surrounding the ability to switch patients, who are stable and doing well on the 
innovator infliximab, to more cost-effective biosimilars. Concerns have previously been 
raised regarding efficacy, safety and immunogenicity, resulting in the formation of ADAs 
once patients have switched to biosimilars.302,303 Some of these concerns were raised 
from specific scientific communities (in this case, gastroenterology) that had issues with 
extrapolations of indications for the biosimilars.304–306 Some of the early switching 
studies from infliximab originator to biosimilar included 1) open cohort studies; 2) 
second year extensions of PLANETAS, a phase 1 study in AS patients, and PLANETRA 
studies, a phase 3 study in RA patients; 3)  NOR-SWITCH study, in which all indications 
were accounted for.307–311 The outcome of the PLANETAS and PLANETRA studies 
Figure 1-27. Quantification by LC-MS/MS. (A) N-glycans. (B) Total mannose-terminated forms. (C) Total 
afucosylated forms. (D) Average KD values for binding to FcγR3a as measured by BLI. (n = 4 lots, mean ± 




were that switching is safe and does not reduce effectiveness of treatment in terms of 
serum concentrations of infliximab and ADA occurrence.307,308,310,311 The NOR-SWITCH 
study was a randomized, controlled trial conducted in order to assess CT-P13’s 
comparability regarding efficacy, safety and immunogenicity for patients who had been 
on stable originator for at least 6 months.309 This study showed that switching to 
Celltrion’s biosimilar (CT-P13) was non-inferior to the originator, meeting acceptability 
specifications within a margin of 15%.312 Fig. 1-28 shows the Forest plot of risk 
difference according to disease, where shifting of results indicate either a favoring of the 
originator (left shift) or the biosimilar (right shift).312 A review on switching studies 
publications in specific disease populations was published in 2018 and as a whole, 
barring some minor outliers, studies on switching to biosimilar infliximab did not lead to 
issues of safety, efficacy or immunogenicity.312 
 
 
Figure 1-28. Forest plot of risk difference according to disease. Figure shows data for the per-protocol 
set. Risk difference adjusted for treatment duration of infliximab originator at baseline. Figure adapted 




 Aspects of Peptide/mAb Formulations and Delivery Devices 
Peptides and proteins are formulated as subcutaneous (SC), intravenous (IV) or 
intramuscular (IM) parenteral injections as they are not orally bioavailable. There are 
many aspects that must be simultaneously considered when developing formulations for 
peptides and proteins including previously mentioned molecular properties, 
manufacturing conditions, storage conditions, potential impurities, routes of 
administration, related administration devices and potential responses to physiological 
conditions.313 
pH is an example of a parameter that is heavily considered during formulation. 
Many of the top 10 mAbs are formulated between pH 5.5 and 7.4.314,315 There is a range 
because the  formulation pH for peptides and proteins has to account for each protein’s 
isoelectric point (pI). If pH is equal to pI (determined by amino acid structure), the 
molecule has a net neutral charge that can lead to unwanted precipitation. While 
precipitation is typically considered a potential impurity, there are select cases, such as 
insulin glargine (Lantus), where isoelectric precipitation is intended upon injection into 
the physiological environment of the body.316 In this case, insulin is modified by the 
attachment of an arginine-arginine tag, increasing the pI from human insulin’s typical 5.6 
to that of approximately 7.0.316,317  
Another factor at play in determining the final protein formulation for parenteral 
solutions is the selection of excipients. Formulation excipients are important given that 
they can prevent degradation. (Fig. 1-29).318 When deciding which excipients are best 
suited for a specific product, manufacturers have to consider the nature of the API. The 




certain excipients. Insulin and insulin analog products serve as good examples of 
molecules requiring significant consideration of formulation complexities. Insulin is 
natively found in equilibrium between the monomer, dimer, tetramer and hexamer 
conformational states, where the equilibrium can be controlled through concentration, 
pH and excipients (Fig. 1-30).319 Insulin analogs have been designed with various 
modifications to effectively remove the ability of these molecules to form dimers. 
Likewise,  some formulations have added phenolic compounds to drive the insulin into 
the hexamer conformation.319 
Figure 1-29. Conformation states of insulin, including the monomer, dimer, tetramer and stable hexamer 
and factors affecting conformational equilibrium. Decreased pH favors the monomer while Zn and insulin 
concentration favor the hexamer. Figure adapted with permission from [319] 
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Figure 1-30. Examples of excipients and their main function in peptide and protein formulations and their 





Sugars have frequently been described as protective excipients against the 
formation of degradants and impurities in protein/peptide formulations. The mechanism 
of protection by sugars, depicted in Fig. 1-31, has been largely attributed to preferential 
exclusion, where the sugar preferentially binds to water in the solution, reducing protein 
solvation propensity.320 Other suggested mechanisms of protection by sugars are 
vitrification, which involves embedding the protein into a glassy matrix to restrict 
mobility, and water replacement, which occurs when the sugar/protein interaction is 
greater than the water/protein interaction at hydrophilic residues, thus removing the 
surrounding water layer.320 Differences between polyol and sugar excipients are also 
likely attributed to differences in the number of H-bond donors and H-bond acceptors as 
well as the variation of hydration volumes occupied by these various excipients.320 
  
  
Figure 1-31. Three proposed theories how sugars may protect proteins from degradation. Vitrification: 
increase of viscosity; Water Replacement: preferential sugar binding with protein; Preferential Exclusion: 




While most excipients are known for their protective effects, there have been  
studies performed where various polyol and sugar excipients have been shown to 
induce protein destabilization as a factor of the protein itself, concentration, and pH.313 
For example, bromelain in the presence of 1M trehalose was observed to exhibit a 2-
state unfolding process. It also exhibited a 3-state unfolding process in the presence of 
1M sucrose.321 The same group then investigated the impact of sucrose and trehalose 
on intrinsic fluorescence. They observed fluorescence quenching by both sucrose and 
trehalose, more so by trehalose, indicating these sugars’ destabilizing effects on 
conformation in a manner previously described.321  
 Lyophilization, which entails freeze drying of a solution into a solid state, has 
been implemented for a number of peptide and protein products to avoid degradations 
commonly prevalent in the liquid state.322–324 While lyophilized cakes are well known to 
achieve adequate shelf-life, the freeze-dry process itself is a source of instability. 
Sugars and polyols are added to reduce degradation and allow rapid freezing below the 
glass transition temperature.325,326 The mechanism of sugar induced stabilization during 
lyophilization has been suggested to occur by two mechanisms: 1) the “glass dynamics 
hypothesis”, where formation of a molecularly dispersed matrix limits mobility, solvent 
induced degradation and bimolecular degradation; and 2) the “water substitute 
hypothesis”, where site specific hydrogen bonds thermodynamically inhibit protein 
unfolding.327–331 Studies comparing the degradation propensity during lyophilization in 
the presence of sucrose or trehalose have been conducted. From these studies it was 
found that sucrose was better at preventing degradation.332 All infliximab products are 




Another major consideration of formulation optimization lies at the interface of 
delivery devices.  Insulin delivery devices serve as a highly useful and comprehensive 
platform that can be translated to the development of future delivery devices for peptide 
and protein products and will thus be used here as an example case. Insulin was initially 
discovered and purified for therapeutic application in 1921 by Banting and Best and has 
since had a long history marked by many advancements in terms of the development of 
alternate products and improvements of delivery devices (Fig. 1-32). Now, devices can 
precisely deliver insulin with minimal invasiveness in a way that improves patient 
compliance.333–338 
Figure 1-32. Major landmark events in the evolution of insulin and insulin delivery devices. Figure adapted 




Initially, insulin was administered via big, heavy reusable syringes that required 
sterilization by boiling prior to use. These reusable syringes were then replaced with 
more specialized needle types, though these were unfavorable due to poor accuracy, 
requirements for multiple daily injections and patient non-adherence. The first pen was 
developed by Novo Nordisk in 1985, offering a more simple, accurate and convenient 
delivery.339,340 First generation pens were available in the market in the 1990’s and have 
been improved by recent advances in smart technology to track and remember insulin 
dosing.341,342 The most recent insulin delivery innovations have been related to 
continuous subcutaneous insulin infusion (CSII) pumps. These pumps are also called 
closed-loops systems, where glucose is constantly monitored, and insulin constantly 
infused. Typical components for these pumps are an insulin reservoir, infusion set and 
tubing, and a catheter for continuous delivery of insulin. The benefit of this technology is 
that the user can specify the program to dispense basal rates while fasting and 
dispense bolus doses prior to meals.343 The two main insulin pumps currently in use are 
Medtronic’s MiniMed System (represented in Fig. 1-33) and Insulet’s Omnipod.344,345  
Figure 1-33. Components of a closed-loop insulin delivery system. Sensor: measures interstitial glucose 
levels; Controller modifies the pump control algorithm in response to the sensor; Pump: infuses insulin 




The main concern for insulin pumps is under- or over-delivery of insulin resulting 
in health consequences, including hyperglycemia and keotoacidosis.346 Incorrect insulin 
delivery can occur via occlusion within the pump, infusion set or tubing. Incidence of 
occlusion has been studied as a function of time and insulin analog used, where 
occlusions were rare in the first 72 hours of infusion, but substantially increased over 
time.347,348 These occlusions have been suggested to be directly related to the 
physicochemical stability of the molecules and their propensity to form fibrils..233,349  
While insulin delivery is common now through pens and continuous pumps, 
delivery of short-term (twice daily) and long-term (weekly) GLP-1 receptor agonists for 
type 2 diabetes therapy remains common via pre-filled pen devices. These devices are 
shown below in Fig. 1-34 along with information on use number, dosage type, max 
dosage strength, whether resuspension is necessary prior to injection and ease of 
use.350,351 GLP1RAs and insulin analogs have been compared in early stage diabetes 
patients in terms of glycemic effectiveness. It was found that there were only minor 
differences such as GLP1RAs having somewhat greater HbA1C reduction.352,353 This 
comparability is important as the current barrier to entry for early stage patients is the 
initialization of therapeutic treatment. GLP1RAs provide a more simplified route of 
administration, whereas insulin analogs commonly require significant education on dose 




Additionally, there are 2 successful co-formulated subcutaneous injections of 
insulin analogs and GLP-1RAs on the market (shown in Table 1-7, Fig. 1-35). Both 
products, Suliqua (Sanofi) and Xultophy (Novo Nordisk), are intended for use in late-
stage type 2 diabetes patients due to the complementary mechanisms of action of the 
components. While relatively new, the growth rate for sales of Xultophy, which 
increased 11% (to $353.6 Mn in 2020), while Suliqua’s sales revenues increased 60.3% 
(to $146 Mn in 2019 [2020 annual report unavailable]), indicate a high ceiling for the 
success of these types of products. In a result of being co-formulated, these products lie 
in a relatively undefined category of biologically derived products in regards to 
regulatory approval pathways.354 Suliqua comes in two dosage forms, containing a 
combination of 300 units of insulin glargine and either 100 or 150 µg of lixisenatide in a 
3mL pre-filled pen.355 Xultophy contains a combination of 300 units of insulin degludec 
and 10.8 mg of liraglutide in a 3mL pre-filled pen.356 Both pens allow for adjustment of 
dosage strength according to desired insulin titration while maintaining the desired 
Figure 1-34. Optical appearance and properties of pen injection devices for approved GLP-1 receptor 




insulin:GLP1RA ratio.355,356 Clinical data has shown that these combinations have 
greater efficacy than either product alone while simultaneously mitigating side effects 
commonly associated with insulin titration.355–357 Additionally, since basal insulin is 
limited to fasting plasma glucose, the benefit of co-administration with GLP1RA’s 
mechanism of action (glucose dependent) has been well-documented in terms of its 
glycemic control.351,358–364 Even so, there is no literature investigating the stability 
profiles of these co-formulations, which seems to indicate that this information has 
remained proprietary. This lack of literature presents an opportunity for further research 
in the diabetes co-formulation and device spaces. 
The following chapters highlight a compilation of analytical techniques that were 
developed to characterize generic peptide and mAb biopharmaceutical products to 
address aspects of chemical and physical degradation in relations to their  regulatory 





Chapter 2: The Effects of pH and Excipients on the Stability of Exenatide 
 Abstract 
Exenatide, a glucagon-like peptide-1 receptor agonist, is the active 
pharmaceutical ingredient in Byetta® and Bydureon®, two type 2 diabetes drug products 
that have generics and multiple follow-up formulations currently in development. Even 
though exenatide is known to be chemically and physically unstable at pH 7.5, there 
lacks a systematic evaluation of the impact of pH and excipients on the peptide solution 
stability. In this study we established analytical methods to measure the chemical and 
physical degradation of the peptide in solution. Exenatide remained relatively stable at 
pH 4.5 when incubated at  37ºC. At pH 5.5-6.5, degradation was driven by oxidation, 
while driven by deamidation at pH 7.5-8.5. Significant aggregation of exenatide at pH 
7.5 and 8.5 was detected by size exclusion chromatography and dynamic light 
scattering. Each pH value greater than 4.5 exhibited unique profiles corresponding to a 
loss of α-helical content and increase of unordered structures. Addition of sugars, 
including mannitol, sorbitol and sucrose, conferred small protective effects against 
monomer loss when incubating at pH 7.5 and 37ºC, as measured by size-exclusion 
chromatography and dynamic light scattering. The results of this study will be useful for 
investigators developing generic exenatide products, peptide analogs and novel 





Exenatide, also known as exendin-4, is a 39-amino acid glucagon-like peptide-1 
(GLP-1) receptor agonist that acts as an incretin mimetic for the treatment of type II 
diabetes mellitus.365 Exenatide retains 53% homology with endogenous human GLP-1, 
while having several amino acid additions and substitutions that give rise to its 
increased serum half-life and potency.263,366,367,368 Exenatide has a partially-folded 
tryptophan (Trp) cage that prevents degradation by NEP 24.11, the main peptidase 
responsible for GLP-1 breakdown in vivo.2 Exenatide is the active pharmaceutical 
ingredient (API) found in AstraZeneca’s Byetta®, a solution formulation for twice-daily 
injection, and the more successful Bydureon®, which consists of exenatide 
encapsulated in poly(lactide-co-glycolic acid) (PLGA) microspheres for weekly 
injection.281,282 In 2019, Byetta® and Bydureon® sales reached over $110 and $549 
million, respectively, in a highly competitive GLP-1 product field.369 There are no FDA 
approved generic versions of Byetta® or Bydureon® currently available. Teva 
Pharmaceuticals reached an agreement with AstraZeneca in 2016, which became 
effective in October 2017, allowing them to manufacture and commercialize a generic 
version of Byetta®. Teva Pharmaceutical’s product has yet to reach the market due to its 
pending ANDA FDA approval.370,371,372 Aside from generics, ongoing research is geared 
towards the development of novel controlled-release formulations of exenatide, such as 
hydrogels and nanospheres, as alternatives to Bydureon®.263,365,373–375  
 A recently published FDA guidance on ANDA submissions for synthetic 
peptides highlights the importance of characterizing product-related impurities that may 




products are specifically mentioned, including glucagon, liraglutide, nesiritide, 
teriparatide and teduglutide. Additionally, the guidance specifically states that analytical 
characterization data should include elucidation of primary sequence, identification of 
chemical impurities, as well as characterization of peptide physicochemical properties 
and oligomer/aggregation states.  
Thus, for both the development of potential generic exenatide drug products and 
novel extended-release formulations, it is critical to understand the chemical and 
physical stability of exenatide. Identifying the peptide’s potential mechanisms of 
degradation allows for the optimization of formulation and selection of appropriate 
manufacturing conditions to avoid the formation of product impurities that may impact its 
safety and efficacy.377,225 At present, there are no systematic studies available in the 
literature investigating exenatide’s solution stability. Based on exenatide’s sequence, 
several deamidation and oxidation hot spots are evident, as highlighted by the following 
underlined peptide residues (HGEGT-FTSDL-SKQME-EEAVR-LFIEW-LKNGG-PSSGA-
PPPS-NH2). Exenatide contains two likely deamidation sites, N28 and Q12, as well as 
two likely oxidation sites, M14 and W24. Only some of these chemical impurities are 
identified and noted in the formulation literature.375,378 Structurally, exenatide contains 
three major domains, including an N-terminal unordered, hydrophilic strand (residues 1-
10), an α-helical coil (residues 11-28) and a C-terminal hydrophobic, proline rich, 
partially-folded Trp-cage (residues 29-39).285 It has been reported that Trp-cage 
disruption is likely responsible for the physical degradation of exenatide.285 While a 
variety of isolated analytical methods for the characterization of exenatide’s purity have 




and their underlying degradation mechanisms is missing.285,379 As such, the goals of this 
study were to identify and characterize exenatide’s chemical and physical degradation 
through the use of accelerated stability testing to elucidate exenatide’s potential 
underlying degradation mechanisms. 
In order to do so, we have developed and implemented several orthogonal 
analytical techniques to investigate the impact of pH and the addition of excipients 
(NaCl, mannitol, sorbitol, and sucrose) on exenatide solution stability during prolonged 
incubation at 37°C. During incubation chemical impurities of exenatide were 
investigated using reverse phase liquid chromatography (RP-LC) and identified by liquid 
chromatography-mass spectrometry (RP-LC-MS). Exenatide physical impurities were 
analyzed by size-exclusion chromatography (SEC), with subsequent examination of 
particle size distributions by dynamic light scattering (DLS). Structural conformation and 
content were analyzed by intrinsic fluorescence (IF) and circular dichroism (CD). 
Overall, our study provides a valuable body of information regarding complex exenatide 
(and peptide) degradation that can be potentially useful for the approval of generic 
exenatide versions and the development of novel sustained release formulation.  
 Materials and Methods 
Exenatide 
Exenatide powder was generously provided by Amneal® Pharmaceuticals 
(Ahmedabad, India). All other materials were purchased from commercial suppliers. 
Exenatide Incubation Conditions 
Exenatide solutions were prepared at a concentration of 0.5 mg/mL in various 30 




acetate [Acetate] (pH 4.5), sodium citrate [Citrate] (pH 5.5), sodium phosphate 
[Phosphate] (pH 6.5), HEPES (pH 7.5) and HEPBS (pH 8.5). To investigate the impact 
of excipients, either salt (154 mM NaCl) or sugar (4.3% w/v mannitol, sorbitol, sucrose 
or trehalose), which were added to exenatide reconstituted at pH 7.5 and compared 
against exenatide reconstituted at pH 4.5 with 4.3% (w/v) mannitol, the negative control. 
Reconstituted exenatide samples at various pH and excipient conditions were subjected 
to 4 weeks of incubation at 37°C. Samples were removed from the incubator at 0-, 1-, 2- 
and 4-week time points and immediately analyzed. Samples were either left undiluted at 
0.5 mg/mL for analysis by dynamic light scattering (DLS) and intrinsic fluorescence (IF) 
or diluted to 0.125 mg/mL prior to analysis by reverse phase liquid chromatography 
(RP-LC), RP-LC-mass spectrometry (RPLC-MS), size exclusion chromatography (SEC 
HPLC), or circular dichroism spectroscopy (CD), as described below. 
Reverse Phase Liquid Chromatography 
Exenatide and its chemical degradation impurities were separated by 
hydrophobicity by RP-LC on a C4-Pack column (YMC) with a Waters 2595 Alliance 
System interfaced to a 2995 Photodiode Array Detector. Samples were filtered and 
injected at a concentration of 0.125 mg/mL at a volume of 50 µL and delivered using a 
mobile phase of acetonitrile (ACN) (0.1%TFA) / H2O (0.1% TFA) at a flow rate of 1 
mL/min with a gradient, ramping from 30 to 55% ACN (0.1% TFA) over 25 minutes. The 
column temperature was held at 40°C. Exenatide samples were detected from UV 






Impurity Identification by Liquid Chromatography with Mass Spectrometry 
Exenatide chemical degradation impurities were separated by RP-LC on the 
same C4-Pack column and analyzed by a dual electrospray ionization equipped Agilent 
6520 Accurate-Mass Q-ToF (Agilent Technologies, Santa Clara, CA). Samples were 
filtered and injected at a concentration of 0.125 mg/mL at an injection volume of 20 µL 
and delivered using a mobile phase of ACN (0.05% TFA) / H2O (0.05% TFA) at a flow 
rate of 0.3 mL/min with a gradient, ramping from 30 to 55% ACN (0.05% TFA) over the 
course of 25 minutes. The column temperature was also held at 40°C. The MS 
parameters include a capillary voltage between 1.2 and 2.0 kV, a ToF-MS range of 300 
– 3200 m/z, a drying-gas temperature of 325 °C, a drying-gas flow rate of 12 L/min, a 
nebulizer pressure of 45 psi, and a fragmentor voltage of 225 V. Total ion 
chromatograms (TIC) were detected at 280 nm, with impurity peak mass extractions 
generated by Qualitative Analysis Mass Hunter Software (Agilent). 
Size Exclusion Chromatography 
Exenatide and its physical degradation impurities were separated by molecular 
weight using SEC on a Superdex Increase 75 10/300 GL column (GE Healthcare) with 
a Waters 2707 autosampler connected to a 1525 binary HPLC pump, interfaced with a 
2489 UV/Vis detector. Samples were filtered and injected at a concentration of 0.125 
mg/mL at a volume of 50 µL and isocratically delivered with a pH 7.4 PBS mobile phase 
at a flow rate of 1 mL/min over 25 minutes. Molecular weights of exenatide peaks were 
determined from a standard calibration, generated from the injection of Uracil (MW 114 
Da), aprotinin (MW 6.5 kD), Cytochrome C (MW 14.5 kD), Carbonic Anhydrase (MW 




(tRs) were correlated with their MWs when imported onto a semi-log plot with the 
generated equation being used to estimate the MW of exenatide monomer and 
aggregate peaks (not shown). Exenatide samples were detected from UV absorbance 
chromatograms that were extracted at 280 nm. 
Particle Size Distribution by Dynamic Light Scattering 
Size distributions of exenatide solutions were determined by DLS on a Zetasizer 
ZSP Nano (Malvern, Worcestershire, UK). 100 µL aliquots of undiluted exenatide (0.5 
mg/mL) were placed into low-volume TruView cuvettes (Biorad, Hercules, CA) at an 
undiluted concentration of 0.5 mg/mL and analyzed for particle size distribution. 
Attenuation and accumulation numbers were automatically optimized for each sample 
by the instrument prior to analysis. Particle size distributions were reported by volume, 
with distributions being combined into 0.3-10, 10-100, 100-500, 500-1000 and 1000+ 
µm size ranges. 
Intrinsic Fluorescence 
Intrinsic fluorescence was used to determine the conformational structure of 
exenatide. Undiluted exenatide samples placed into a QS 1.5 mm quartz cuvette 
(Hellma, Mullheim, Germany) were analyzed at an undiluted concentration of 0.5 mg/mL 
on a SpectraMax M3 (Molecular Devices, San Jose, CA) plate/cuvette reader. The 
fluorescence was measured using a wavelength emission range of 280 – 450 nm and 
an excitation wavelength of 270 nm while obtaining fluorescence at 6 flashes per read. 
Far-UV Circular Dichroism 
The secondary structure of exenatide samples were determined on a J-815 




temperature was held at 37°C using a Peltier attachment. CD spectra were averaged 
from 5 collected scans over a wavelength range of 245 to 195 nm, with an accumulation 
rate of 20 nm/min and a data integration time (DIT) of 4 seconds. Percent α α-helix, β-
sheet and unordered secondary structures were quantified using a third-party Spectra 
Manager Suite (JASCO) add-in, CDPro analysis. In this software, the CONTIN method 
was chosen, using soluble-membrane protein 56 (SMP 56) as the reference protein for 
secondary structure analysis. 
 Results 
Forced Chemical Degradation 
Identification of Degradation Impurities by LC-MS QToF 
LC-MS-QToF was implemented to analyze potential exenatide chemical impurity 
formation. Short-term accelerated exenatide degradation was induced by reconstituting 
exenatide at pH 8.5 and incubating at an elevated temperature of 60°C for 24 hours. 
Exenatide’s parent peak was separated from its chemical impurities by reverse phase 
liquid chromatography (RP-HPLC) on a C4 Pack column. Fig. 2-1A depicts a total ion 
chromatogram (TIC) with the respective peak identities. A total of 9 different peaks were 
identified for exenatide (Fig. 2-1B-J) relative to its average mass of 4816 Da, which 
included the formation of a PyroQ impurity and different combinations of oxidations and 







Peak F was identified as exenatide’s native state parent peak (+0); peaks C and 
E, single (+16) and double oxidations (+32), respectively; peaks B and D, a combination 
of an oxidation and a deamidation (+17); peaks G, H, and I, a single deamidation (+1); 
and peak J, PyroQ formation from a glutamine (Q12). A previously published study has 
confirmed that the primary deamidation site for exenatide is N28 when incubated in pH 
7.4 phosphate buffer at 37°C for 56 days.284 As expected, deamidations occurred at the 
N28 G29 residue combination, a prolific peptide and protein deamidation 
hotspot.225,224,381 The major deamidation impurity (Peak H) in both studies had been 
previously identified as the conversion to L-isoAspartate [L-isoAsp], while the minor 
impurity (peak G) was identified as the conversion to D-isoAspartate [D-isoAsp] 284.  We 
would expect that the observed oxidation is occurring at Met14, another primary 
degradation hotspot that has been implicated to affect peptide and protein 
stability.225,224,381,382 Additional LS-MS/MS studies are needed to identify specific 
oxidation impurities. 
Figure 2-1. Identification (w/ deconvoluted masses) of exenatide’s chemical impurities by RPLC-MS QToF 
following incubation of peptide solution (pH 8.5) at 60°C for 24 hours. RP-HPLC C4 UV absorbance (A) 
total ion chromatograms (TIC) and (B-E, G-J) exenatide chemical impurities and their reported respective 
mass shifts, which include a combination of oxidation, deamidation and PyroQ formation, from (F) native 




Forced Chemical Degradation at 37°C 
Chemical degradation profiles were determined for exenatide solutions that were 
reconstituted between pH 4.5 - 8.5 and subject to incubation at 37°C for 4 weeks. 
Exenatide’s parent peak was separated from its chemical impurities on an RPLC 
column. Parent peak (Fig. 2-2A) and oxidation (Fig. 2-2B) and deamidation (Fig. 2-2C) 
impurities were quantified over the course of incubation. 
When incubated at pH 4.5 and 5.5, the exenatide parent peak remained relatively 
stable over the course of incubation, decreasing to 88.6 ± 0.7% and 87.0 ± 1.4%, after 
28 days of incubation, respectively. The relative stability of exenatide at low pH was 
expected as Byetta® is commercially formulated in an acetate buffer solution of pH 4.5.  
On the other hand, a rapid, pH-dependent degradation of exenatide was observed when 
reconstituted at pH 6.5, 7.5 and 8.5. We also observed a loss in total AUC during 
incubation indicating some precipitation occurring at pH 7.5 and 8.5 over 4 weeks 
decreasing to an average of 71.9 ± 10.1 % and 70.9 ± 9.8 % relative to day 0, 
respectively (Fig. 2-3B). This precipitation was confirmed by appearance of larger 
particulates during incubation as measured by DLS.  
Figure 2-2. Kinetics of chemical degradation determined by RP-LC separating (A) parent peak from (B) 
oxidation and (C) deamidation chemical impurities during incubation of exenatide solutions pH 4.5 – pH 





Chemical degradation appears to be mainly oxidation driven from pH 4.5 to 6.5. 
As previously mentioned, we would expect that this would likely occur at the methionine 
residue. Oxidation was identified by the presence of a split peak around a retention time 
of 6.5 minutes, with total oxidation being the summation of peaks that elute prior to the 
parent peak (Supp. Fig. 2-3A). Over the course of long-term incubation, chemical 
degradation of exenatide at pH 7.5 and 8.5 also appears to be driven mainly by 
deamidation, with the parent peak decreasing to 30.9 ± 1.6% and 20.3 ± 1.1% and 
deamidation impurity peaks increasing to 67.0 ± 2.2% and 77.8 ± 1.9%. We would 
expect the formed impurity to occur at the N28 residue, as it is followed by a glycine, a 
Figure 2-3. A) RP-LC chromatograms after 4 weeks of incubation and B) AUCs (relative to day 0) and C) 
SEC-LC chromatograms after 4 weeks of incubation and D) AUCs (relative to day 0) for exenatide 




well-known deamidation hotspot combination.225,224 A major deamidation impurity, 
previously identified as the conversion to L-isoAsp, formed at a retention time of 12.4 
minutes while a minor deamidation impurity, previously identified as conversion to D-
isoAsp, formed at a retention time of 11.8 minutes (D-isoAsp). It has been previously 
reported that isolated L-isoAsp and isolated D-isoAsp impurities exhibit weaker GLP1 
receptor binding.284  
Forced Physical Degradation at 37°C 
Aggregation has been identified as an important instability mechanism in both 
peptides and proteins.225 Specifically, aggregation has been suggested to occur through 
the disruption of exenatide’s partially-folded, protective Trp cage though studies have 
remained lacking.285 Physical degradation profiles were also determined for exenatide 
solutions reconstituted between pH 4.5 - 8.5 that were subject to incubation at 37°C for 
4 weeks. An SEC column was used to separate and quantify monomers (Fig. 2-4A), 
aggregates (Fig. 2-4B) and fragments (Fig. 2-4C) over the course of incubation. 
Physical degradation, in terms of monomer loss, appears to occur in a pH 
dependent manner. Exenatide incubated at pH 4.5 and 5.5 remained relatively stable 
Figure 2-4. Kinetics of physical degradation determined by SEC-LC, separating (A) monomer from (B) 
aggregate and (C) fragment physical impurities of exenatide reconstituted at pH 4.5 – pH 8.5 after 




over the course of incubation, with monomer decreasing to 95.7 ± 0.8% and 94.2 ± 
0.1%, respectively, after 4 weeks of incubation. Again, the relative stability of exenatide 
at low pH was expected as Byetta® is commercially formulated in acetate buffer (pH 
4.5).383   Physical degradation tendencies vary significantly at pH 6.5 and above in terms 
of aggregation and fragmentation. Exenatide reconstituted at pH 6.5 tends to form 
fragments after 2 and 4 weeks of incubation, increasing to 9.0 ± 2.5% and 30.3 ± 
16.4%, rather than aggregates, which increased slightly, 0.6 ± 0.2% and 8.0 ± 1.9%, 
respectively. On the other hand, exenatide reconstituted at pH 7.5 forms mainly 
aggregates, increasing to 50.6 ± 1.8% and 77.4 ± 2.9% after 2 weeks and 4 weeks of 
incubation, respectively. The total AUCs for SEC chromatograms decreased over the 
course of incubation at pH 7.5 and 8.5 reaching 61.6 ± 0.3 % and 61.1 ± 12.1 % of the 
initial values, indicating peptide precipitation.  
Characterizing Particle Size Distribution by DLS 
To further characterize pH-dependence of aggregation of exenatide during 
incubation, particle size distributions were determined by DLS. Particles were measured 
by volume since intensity measurements were skewed by exenatide’s non-spherical 
nature. Particles were combined into 0.3-10, 10-100, 100-500, 500-1000 and 1000+ µm 
size ranges with distributions shown for an incubation over the course of 4 weeks at 
37°C (Table 2-1). While DLS measurement is inherently highly variable, several trends 
were observed, corroborating the formation of oligomers during incubation at higher pH 
values as had been observed through the reduction of SEC and C4 AUCs. For pH 4.5 
and 5.5, peptide was found to be primarily in the 0.3-10 µm size range throughout 




weeks of incubation. At higher pH values (6.5 to 8.5) the reduction of the 0.3-10 µm 
fraction was observed during incubation, as well as an increase in particulates of 10-
1000 µm size range. 
Structural Analysis by IF and CD 
Understanding the underlying structural changes of peptides is especially 
important when investigating degradation profiles, as they provide more insight into the 
impact of chemical and physical degradation profiles on structure. Tertiary and 
Table 2-1. Particle size distribution determined by DLS (by volume) and separated into 0.3 – 10, 10 – 100, 
100 – 500, 500 – 1000 and 1000+ µm size ranges for exenatide that was reconstituted at pH 4.5 – 8.5 




secondary structures of exenatide samples reconstituted at pH 4.5 - 8.5 were analyzed 
by IF and CD over 4 weeks of incubation at 37°C (Fig. 2-5). 
IF was used to qualitatively investigate exenatide’s conformational structure 
when subject to incubation, where both increases of intrinsic fluorescence and a right 
shift of maximum emission wavelengths (red shift) indicated unfolding through 
increased solvent exposure of Trp (Fig. 2-5A-C). Trp solvent exposure is an important 
structural indicator in exenatide, as the Trp is typically buried in a proline rich C-terminal 
cage that stabilizes exenatide285. Initially, the intrinsic fluorescence profiles were very 
Figure 2-5. Structural and conformational changes characterized and measured by (A-C) intrinsic 
fluorescence and (D-F) circular dichroism, with secondary structures (G-I) quantified by CDPro analysis (n 




similar for all pH conditions in terms of fluorescence intensity (~1500 units) and 
maximum emission wavelengths (333 nm). After 2 weeks and 4 weeks of incubation at 
37°C, the IF profiles of exenatide reconstituted at pH 4.5 and 5.5 were unchanged, 
retaining maximum emission wavelengths of 333 nm. After 4 weeks of incubation at pH 
6.5, there was an observable right shift of maximum emission wavelength to 341 nm, 
though with a decrease of fluorescence intensity, which may potentially indicate both 
Trp cage unfolding and structural rearrangement. Exenatide showed a significant, time-
dependent, increase of fluorescence intensity and a right shift of maximum emission 
wavelength at elevated pHs. Following 2 weeks and 4 weeks of incubation, exenatide 
reconstituted at pH 7.5 showed an increase of fluorescence intensity to 2150 and 2425 
units, respectively, and a right shift of maximum emission wavelengths to 342 and 348 
nm, respectively. A similar change was seen for exenatide reconstituted at pH 8.5 
where changes were even more drastic than pH 7.5 in terms of fluorescence intensity, 
increasing to 2390 and 2835 units, respectively, and maximum emission wavelengths, 
shifting to 344 nm to 354 nm, respectively. Together, they indicate both unfolding and 
an increase of Trp solvent exposure. 
CD is useful in combination with IF, providing further information on underlying 
secondary structural changes, including shifts of distributions between of α-helical, β-
sheet and unordered content. Exenatide samples were qualitatively measured by CD 
(Fig. 2-5D-F) and then quantified by CDPro analysis (Fig. 2-5G-I). At week 0, base 
emission wavelengths were 208 nm for all samples. Quantified secondary structures 
were similar for all pH conditions, apart from pH 5.5. Over the course of incubation, 




quantified secondary structures over the course of incubation showed a loss of α-helical 
content (72.3 ± 6.1% at 0 weeks vs 57.1 ± 1.6% after 4 weeks) and increase of 
unordered content (22.7 ± 2.8% at 0 weeks vs 37.1 ± 2.1% at 4 weeks). Exenatide 
reconstituted at pH 5.5 also retained a base emission wavelength of 208nm. While 
having a lower initial amount of α-helical content, the distribution of secondary structural 
content remained unchanged over the course of incubation. The α-helical content for 
exenatide reconstituted at pH 6.5, 7.5 and 8.5 decreased in a pH dependent manner 
from 70.9 ± 2.2%, 76.6 ± 2.6% and 73.7 ± 3.4% at week 0, respectively, to 30.1 ± 5.1%, 
25.4 ± 1.3%, and 18.75 ± 4.0% after 4 weeks, respectively. Loss of α-helical content 
was generally matched by an increase of unordered content for the exenatide samples 
reconstituted at pH 6.5-8.5.  
The Impact of Excipients on Degradation at pH 7.5 
It is known that the addition of sugar excipients can generally offer protection 
from peptide and protein aggregation during freeze/thaw cycles and long-term storage, 
while other excipients, like salt, may negatively induce aggregation.225,224 The impact of 
these types of excipients on chemical and physical degradation profiles was 
investigated for exenatide reconstituted at pH 7.5 and incubated for 4 weeks at 37°C. 
Common excipients, including salt (NaCl) and various sugars (mannitol, sorbitol and 
sucrose) were added at iso-osmolar concentrations (154 mM and 4.3% w/v, 
respectively), to determine if they would alter degradation profiles. Parent peak (Fig. 2-
6A), oxidation (Fig. 2-6B) and deamidation (Fig. 2-6C) profiles for exenatide after 4 




Exenatide reconstituted at pH 4.5 with 4.3% mannitol was the negative control 
(Byetta® formulation). Our results indicate that the addition of different excipients had 
limited effects on chemical exenatide’s stability at pH 7.5. Compared to the negative 
control, where 87.8 ± 0.8% of the parent peak remained intact, pH 7.5 formulations had 
significant parent peak loss, decreasing to approximately 30% after 4 weeks of 
incubation. All formulations experienced similar levels of oxidation during the incubation 
period. The negative control contained significantly less deamidated species compared 
to pH 7.5 formulations (approximately 3% vs. 60%) after 4 weeks of incubations. We 
also observed some total AUC loss, decreasing to an average between approximately 
60 and 80% at 4 weeks relative to day 0 for all pH 7.5 formulations, indicating some 
precipitation occurring over the course of incubation (Fig. 2-7B). 
Figure 2-6. Kinetics of degradation determined by RP-LC and SEC-LC, with RP-LC separating (A) parent 
peak from (B) oxidation and (C) deamidation chemical impurities and SEC-LC separating (D) monomer 
from (E) aggregate and (F) fragment physical impurities of exenatide reconstituted at pH 4.5 w/ mannitol 
and pH 7.5 with specified excipients after incubation at 37°C for 4 weeks. (n = 3, mean ± SEM, * p < 0.05 





An SEC column was used to separate and quantify monomers (Fig. 2-6D), 
aggregates (Fig. 2-6E) and fragments (Fig. 2-6F) over the course of incubation. SEC 
analysis after 4 weeks of incubation revealed significant monomer loss for all pH 7.5 
formulations compared to the negative control after 4 weeks (approximately 20% vs. 
95% remaining). Monomer loss was significantly greater for the pH 7.5 formulation 
without excipient (18.3 ± 0.1%) than formulations containing mannitol (26.3 ± 2.0%), 
sorbitol (25.4 ± 1.1%) and sucrose (24.4 ± 1.3%) (p < 0.05 for all solutions), indicating 
protective abilities of these excipients against physical instability, though not against 
Figure 2-7. RP-LC chromatograms after 4 weeks of incubation and B) AUCs (relative to day 0) and C) 
SEC-LC chromatograms after 4 weeks of incubation and D) AUCs (relative to day 0) for exenatide 
samples reconstituted at pH 4.5 w/ mannitol vs pH 7.5 w/ specified excipients over the course of 




chemical instability. Exenatide physical impurities were present mainly in the form of 
aggregates at pH 7.5.  
Further characterization of peptide aggregates was performed using DLS. Our 
data showed that exenatide was very stable at pH 4.5, with particles staying in the 0.3-
10-µm size range for the entire incubation. At pH 7.5, sucrose, mannitol, and sorbitol 
exhibited significant stabilizing effects on exenatide against aggregation, as indicated by 
100% of particles present in the 0.3-10 µm size range after 4 weeks compared to 
excipient-free formulation which had 67% in this size range (Table 2-2). The NaCl 
formulation resulted in significant shifts in particle size distribution, with most particles 
being in the 10-100 µm range (NaCl) after 4 weeks. 
Subsequent structural analysis by IF and CD revealed the pH 4.5 mannitol 
formulation to be the most stable. All pH 7.5 formulations experienced a significant red 
shift of maximum emission wavelength as well as an increase in maximum fluorescent 
intensity after 4 weeks, indicative of unfolding and Trp solvent exposure (Fig. 2-8A,D). 
Table 2-2 Particle size distribution determined by DLS (by volume) and separated into 0.3 – 10, 10 – 100, 
100 – 500, 500 – 1000 and 1000+ µm size ranges for exenatide that was reconstituted at pH 4.5 w/ 




CD Pro analysis showed no observable differences between excipient spectra at 0 (Fig. 
2-8) and 4 weeks (Fig. 2-8E) of incubation. CD pro analysis prior to incubation showed 
that all formulations contained similar percentages of α-helix, β-sheet, and unordered 
content (Fig. 2-8C). After 4 weeks, the secondary structural content was additionally 
similar across all formulations, resulting in the formation of unordered content and β-
sheet structures. (Fig. 2-8F). Taken together, the addition of sucrose, mannitol, and 
sorbitol to exenatide formulation at pH 7.5 shown modest stabilization effect against 
monomer loss, but only by SEC. 
 Figure 2-8 Structural and conformational changes characterized and measured by intrinsic fluorescence 
(A,D) and circular dichroism (B,E), with secondary structure quantified by CDPro analysis (C,F) for 
exenatide that was reconstituted at pH 4.5 w/mannitol and pH 7.5 w/ specified excipients after incubation 





Exenatide appears to undergo a rapid, pH-dependent degradation at pH 6.5 and 
above while remaining relatively stable at lower pH over the course of incubation. 
Analogously, endogenous GLP-1 has also shown degradation when pH was slightly 
increased, though pH was adjusted on a smaller scale.384 While loss of exenatide’s 
parent peak and monomer detected by LC is pH-dependent, impurity formation varied, 
with mainly oxidation and fragmentation occurring at pH 6.5, deamidation and 
aggregation at pH 7.5 and 8.5. Particle size distributions determined by DLS seemed to 
further confirm these relationships, indicating size distribution shifts toward the 
formation of oligomers at higher pH values. Additionally, trends for structural 
degradation of exenatide reconstituted at an elevated pH seemed to match, where 
exenatide reconstituted at pH 6.5 and 8.5 had greater amounts of β-sheet formation 
than exenatide reconstituted at pH 7.5. While deamidation is rapidly occurring at pH 7.5 
and above, it remains undetermined whether significant unfolding of structure is related 
to, or simply simultaneously occurring with, deamidation. Additionally, though not 
statistically significant, we observed a trend of total AUC loss after 4 weeks of 
incubation by C4 and SEC for exenatide reconstituted at pH 6.5 – 8.5.  This seems to 
indicate some amount of larger aggregate formation occurring at elevated pH over the 
course of incubation further confirming DLS findings.  
Exenatide chemical impurities were identified by LC-MS QToF, revealing several 
deamidations (+1 mass shift), oxidations (+16/+32 mass shifts) oxidation/deamidation 
mixtures (+17 mass shift) and pyro-Q impurity formations. However, we have limited 




exenatide contains two potential deamidation and two potential oxidation sites. We 
identified three deamidation peaks based on LC-MS QTOF (mass shift +1), with one 
major peak that rapidly increases at high pH in a solution incubated at an elevated 
temperature. We speculate that the major deamidation occurred on asparagine (N28) 
as this amino acid is followed by glycine (G29), the most prominent deamidation hot 
spot. 237,84 Another deamidation is potentially occurring on the glutamine residue (Q13). 
In addition, different C4 deamidation peaks with a mass shift of +1 could be attributed to 
conformational peptide changes resulting from the formation of two different asparagine 
deamidation products (aspartic or iso-aspartic acid).225 In terms of oxidation, an impurity 
that has not been previously studied, we have identified a +32 mass shift that could be 
attributed to single oxidation of two residues or a double oxidation of one residue. It 
appears that this oxidation is likely forming at the M14 residue, as the Trp-cage protects 
the Trp at low pH. Additional analysis of isolated impurity peaks is needed to confirm 
exenatide degradation product identities. 
Our experiments investigating the impact of different excipients on exenatide’s 
stability at pH 7.5 revealed the limited ability of excipients to stabilize exenatide as well 
as their varied effects on exenatide’s degradation profile. We did observe minor 
stabilizing effects protecting against the loss of monomer by mannitol, sorbitol and 
sucrose, though they were unable to prevent chemical degradation. The main impurities 
observed were aggregation and deamidation for all formulations after 4 weeks of 





While we have determined a pH-dependence in exenatide’s degradation kinetics, 
we have not fully defined the mechanism of peptide aggregation. Currently, we propose 
that degradation occurs through two different mechanisms. At low pH, M14 would seem 
to undergo oxidation as the Trp is protected by the Trp cage. M14 oxidation in 
exenatide’s helical region could lead to alpha helix disruption and potential degradation 
and fragmentation, which was observed at pH 6.5. At high pH, N28 appears 
deamidated, as shown by RPLC, and unfolded at the Trp-cag, resulting in an increase 
of unordered structures by CD, which then can lead to further degradation including 
dimerization, formation of larger aggregates and precipitation, as seen by loss of AUC.  
Considering the recently published FDA guidance for synthetic peptides, and previously 
published literature about exenatide’s ability to elicit immunogenic responses, further 





Chapter 3: Biosimilarity Under Stress: A Forced Degradation Study 
 Abstract 
Remsima™, marketed as InflectraTM  in the US, (infliximab) is the first biosimilar 
monoclonal antibody (mAb) approved by the European Medical Agency and the Food 
and Drug Administration. Remsima™ is highly similar to its reference product, 
Remicade®, with identical formulation components. The 2 products, however, are not 
identical; Remsima™ has higher levels of soluble aggregates, C-terminal lysine 
truncation, and fucosylated glycans. To understand if these attribute differences could 
be amplified during forced degradation, solutions and lyophilized powders of the 2 
products were subjected to stress at elevated temperature (40–60°C) and humidity (dry-
97% relative humidity). Stress-induced aggregation and degradation profiles were 
similar for the 2 products and resulted in loss of infliximab binding to tumor necrosis 
factor and FcγRIIIa. Appearances of protein aggregates and hydrolysis products were 
time- and humidity-dependent, with similar degradation rates observed for the reference 
and biosimilar products. Protein powder incubations at 40°C/97% relative humidity 
resulted in partial mAb unfolding and increased asparagine deamidation. Minor 
differences in heat capacity, fluorescence, levels of subvisible particulates, deamidation 
and protein fragments were observed in the 2 stressed products, but these differences 
were not statistically significant. The protein solution instability at 60°C, although quite 
significant, was also similar for both products. Despite the small initial analytical 




kinetics. Thus, our results show that the 2 products are highly similar and infliximab's 
primary sequence largely defines their protein instabilities compared with the limited 
influence of small initial purity and glycosylation differences in the 2 products. 
 Introduction 
Looming patent expirations for lucrative protein drugs have led to a surge in 
development, regulatory filings, and approvals for biosimilar products.386 Infliximab was 
the first biosimilar monoclonal antibody (mAb) to receive approval by the European 
Medical Agency and, recently, by the US Food and Drug Administration.300,3 The 
approved biosimilar Remsima™, Inflectra™ in the US, is manufactured by Celltrion 
(Incheon, South Korea) and is a copy of Remicade®, manufactured by Janssen. 
Infliximab is approved for various indications, including rheumatoid arthritis, ankylosing 
spondylitis, and inflammatory bowel diseases such as ulcerative colitis and Crohn's 
disease.387 Detailed analytical comparison of Remicade® and Remsima™ shows 
significant product similarity, apart from differences in glycan composition, as well as 
minor differences in levels of soluble aggregates and basic charged 
variants.41,135,300,348 These product variances are not surprising since the biosimilar 
protein is produced using a different clone of Sp2/0 murine hybridoma cell line, a 
different manufacturing processes, and in different facilities.43,300,8 Additionally, while the 
formulations of the 2 products are identical, the final lyophilization process as well as 
the sources for formulation excipients are likely different. These process and excipient 
differences could result in various levels of reactive species, such as reduced sugars 




storage. These factors may all contribute to product quality, safety and efficacy, and 
ultimately make demonstrating biosimilarity challenging. 
One strategy to evaluate biosimilarity is to compare biosimilar and reference 
products in forced degradation studies using thermal, mechanical, or chemical 
stressors.389–391 Forced degradation studies are usually performed in the development 
cycle of biotherapeutics to select formulation excipients, develop dosage forms, and 
determine product shelf life.389,391 These studies are also used during manufacturing 
process validation to define hold times, for process intermediates, and in analytical 
method development to define resolving abilities of various assays. The stress testing 
conditions used for these analyses are far more extreme than the actual physical and 
thermal stresses that the product vials are exposed to during manufacturing, transport, 
storage, and handling by physicians or patients. The results from stress testing likely 
over-exaggerates the extent of product difference and should, thus, be interpreted with 
caution. However, stress conditions accelerate protein degradation, enrich impurity 
levels, and thereby improve analytical resolution to aid with analytical development. 
Ultimately, examination of protein products under stressed conditions give insights into 
the mechanisms of how these proteins may unfold, lose efficacy, aggregate, and 
become immunogenic. Forced degradation studies generate valuable analytical data, in 
relatively short periods of time, to compare biosimilar and reference products and to 
help link protein structural information with product quality, safety and efficacy.389,391 
In this study, we use Remicade® and Remsima™ as a model reference and 




manufacturing process between the 2 products could influence protein instability upon 
stress degradation. Comparisons between batch release data of biosimilar and 
reference product provide the most important information for assessment of product 
safety, efficacy and biosimilarity. However, minor structural differences between 
products may be amplified upon stressing, and such stress testing could provide 
additional information for biosimilarity evaluation. When protein products are stressed, 
their degradation pathways and the extent of modifications are determined by multiple 
factors, including protein sequence, physical state, formulation, excipients, and the 
levels of initial impurities. When formulations of innovator and biosimilar products are 
different, forced degradation studies could be particularly important in determining 
biosimilarity. While the primary sequence, physical state and formulations are identical 
for Remsima™ and Remicade®, the levels of various impurities such as soluble 
aggregates, charged isoforms, misassembled light chain-heavy chain impurities and 
glycation levels are different.136,300 These initial impurities could serve as initiators to 
facilitate further protein unfolding and degradation upon stress. Hence, it could be 
reasonably expected that a stress-testing based strategy that compares reference and 
biosimilar products could help to both accentuate product differences and delineate 
between protein degradative pathways that are defined by protein structure versus 
product impurities. Consequently, we expect the stress degradation studies to provide 
further insight into similarity and differences between the 2 products. 
To test our concept, we used elevated humidity and temperature incubation to 
assess how multiple lots of Remsima™ and Remicade® compared. Rigorous analytical 




and chemical (oxidation, deamidation) changes brought on due to stressing, to 
understand infliximab's degradation pathways, and identify modification “hot spots” in 
the sequence. Lastly, the effect of these modifications on biologic activity was quantified 
using tumor necrosis factor (TNF) binding ELISA and FcγRIIIa binding assays. 
Collectively, our results provide both a biosimilarity comparison and information about 
degradation mechanisms for infliximab in the lyophilized powder form. 
 Materials and Methods 
Infliximab Products 
Remicade® was purchased from the University of Michigan Hospital Pharmacy 
(Ann Arbor, MI) and Remsima™ was acquired from Celltrion (Incheon, South Korea). 
Both Remsima™ and Remicade® are supplied as lyophilized powders in vials 
containing 100 mg of infliximab, 500 mg of sucrose, 0.5 mg Tween 80, and 8 mg 
phosphate buffer salts.387,392 The lot numbers and expiry dates of the products used in 
this study are listed in Table 3-1. All forced degradation studies were conducted within 
the expiry dates of the samples. Samples were reconstituted using pure WFI (Thermo-
HyClone) to a concentration of 1 mg/mL unless specified otherwise. All chemical 






Protein Stress Study Set-up 
 Powders of Remicade® and Remsima™ contain ∼16% of protein by weight. Vials 
of both products were opened and aliquoted in 1.5 mL Eppendorf tubes (∼6.25 mg of 
powder or 1 mg of infliximab in each tube). Saturated solutions of NaBr and K2SO4 in 
distilled water were prepared to simulate 53% and 97% RH, respectively.393 Desiccant 
was used to simulate dry conditions. The infliximab powders in open tubes were placed 
in desiccators at a specific RH and incubated at 40°C for 1, 2, or 4 weeks. Samples 
were removed from the desiccators and reconstituted with WFI to 1 mg/mL. 
Reconstituted samples were further aliquoted for the various analytical assays and 
stored at either 4°C or −80°C until analysis. Reconstituted proteins were also subject to 
thermal stress and are detailed in the supplemental information. 
Size Exclusion Chromatography 
 SEC was performed using a Waters Binary HPLC pump 1525 equipped with 
Waters auto-sampler 2707 and UV/visible detector 2489. TSK Gel 3000 SWxl column 
(Tosoh 7.8 mm × 30 cm, 5 µm). The mobile phase, phosphate-buffered saline (PBS; pH 
7.4), was delivered at 1 mL/min. Protein samples were filtered through 0.45 μm filter 




(Millipore) before injection. A 25 μL injection volume was used and the UV signal was 
monitored at 210 and 280 nm. The area under the curve was used to calculate the 
percentage of monomer, aggregates and fragments. The monomer content for 
unstressed samples served as the 100% reference and the loss of monomer content at 
each stressed time point was calculated by decrease of monomer peak area. 
Circular Dichroism 
CD was performed using a Jasco J-815 CD spectrometer equipped with 
temperature controller (CDF-426S/15) and Peltier cell at 25°C. The samples were 
diluted to 0.1 mg/mL for near UV and to 0.5 mg/mL for far UV measurements. The 
samples were measured in quartz cuvettes (Hellma) with a path length of 1 mm for far 
UV and 1 cm for near UV. The spectra were collected in continuous mode at a speed of 
50 nm/min, bandwidth of 1 nm and a DIT of 1 s. The average of 10 scans were 
reported. Blank buffer without the antibody was subtracted from each spectrum using 
the Jasco spectra manager software (Version 2.1). The raw data were converted to 
mean residual ellipticity (MRE) using the following equation: 
[𝜃𝜃]𝑚𝑚𝑚𝑚𝑚𝑚,𝜆𝜆 = 𝑀𝑀𝑀𝑀𝑀𝑀 𝑥𝑥
𝜃𝜃𝜆𝜆
10 𝑥𝑥 𝑑𝑑 𝑥𝑥 𝑐𝑐
 
where θλ is the observed ellipticity in degrees at wavelength λ, d is the path length in 
cm, c is the concentration in g/mL, and mean residual weight (MRW) is 110 for 
infliximab. Data smoothing was performed using GraphPad Prism Software (Version 
6.07) using a 0th order polynomial with 4 neighbors at each point. 
Intrinsic Fluorescence 
 Intrinsic fluorescence was performed with a Jasco J-815 spectrometer equipped 




0.1 mg/mL and were measured in black window quartz cuvettes (Hellma) with a path 
length of 1 mm. The spectra were collected in continuous mode with a data pitch of 
5 nm, scan speed of 50 nm/min and a DIT of 1sec; data were averages of 5 scans. The 
excitation wavelength was 280 nm and emission spectra were collected from 300 to 
400 nm, with a gain voltage of 850 V. Data smoothing was performed using GraphPad 
Prism Software (Version 6.07) using a 2nd order polynomial with 4 neighbors at each 
point. 
Gel Electrophoresis 
 Selected samples were analyzed by non-reducing and reducing SDS-PAGE to 
examine for presence of mAb aggregates and fragments. Samples (∼10 µg) were 
mixed with NuPAGE LDS sample buffer, at 3:7 sample: loading buffer ratio and 
denatured at 90°C for 3 minutes before gel loading. For reduced samples, 5% v/v β-
mercaptoethanol was added before heat denaturation. Samples were run on Invitrogen 
PowerEase 500 with NuPAGE 4–12% BisTris gel. BioRad Precision Plus Protein™ All 
Blue Standards were used for molecular weight controls. Gels were stained using 
Thermo Pierce Silver Stain Kit and accompanying protocol and analyzed using 
Fluorchem M (ProteinSimple). 
Nanoparticle Tracking Analysis 
 NTA (Nanosight NS300, Malvern) was used to quantify subvisible particulates in 
protein samples. The NS3000 was fitted with a SCMOS camera, a 405 nm blue laser 
and the sample chamber. The samples were diluted 10-fold before analysis and 
transferred to sterile syringes (BD) before injection into the sample chamber. The 




sample analysis. The sample results were averages of three 60s runs measured at 
0.1 mL/min flow rate and were analyzed using the NTA 3.0 software. 
Modulated Differential Scanning Calorimetry 
Modulated DSC (Discovery, TA Instruments, New Castle, DE) was used to 
determine the Tg and heat of enthalpy of the lyophilized powders. Sample powders 
(∼10 mg) were sealed in hermatic aluminum pans. The measurements were performed 
at a heating rate of 2 °C per min from 0 to 180 °C under a nitrogen gas flow of 
25 mL/min. The modulation amplitude was 0.5 °C and the period was 40 s. The Tg and 
enthalpy were obtained by fitting data with TA Trios software (v4.1.1). 
Nano-differential Scanning Calorimetry 
The thermal melt profiles for stressed and unstressed samples of Remicade® and 
Remsima™ were measured using TA Instruments nDSC equipped with an autosampler. 
The thermograms were obtained using a scan rate of 1°C/min from 10°C to 100°C. The 
thermograms were analyzed using TA NanoAnalyze software (v2.4.1) after blank buffer 
subtraction using multiple scaled 2 state models to determine the 3 transition melt 
temperatures. 
Thermal Degradation 
Remicade and Remsima powders were reconstituted in water for injection (WFI) 
to a concentration of 1 mg/ml. Samples were incubated at various temperatures 4°C, 
25°C, 40°C and 60°C (n=4 per) for up to 1 week. Periodically, formation of soluble 
aggregates and partial unfolding were monitored by SEC and Thioflavin-T (ThT) 
fluorescence assay, respectively. Follow on studies were performed at 60°C, the most 




variability as well as the differences between the two products. Samples were incubated 
for 3 h and protein aggregation was examined by SEC and ThT fluorescence analyses 
periodically. Following 2 h incubation, subvisible particulates were analyzed by 
Nanoparticle Tracking Analysis (NTA). Samples incubated for 1 h were digested and 
analyzed by LC-MS/MS to assess individual amino acid deamidation, oxidation and 
dioxidation levels. 
Thioflavin-T Fluorescence Assay 
Thioflavin-T (ThT) is a fluorescent dye known to bind to beta sheet/hydrophobic 
rich regions of proteins and increase the fluorescence intensity1. ThT assay was 
performed to assess the exposure of hydrophobic regions and protein unfolding and 
aggregation as follows: 50 x Stock ThT (Sigma) solutions were prepared by dissolving 8 
mg of ThT in 10 mL of 10 mM phosphate/150 mM NaCl and stored away from light. 1x 
ThT working solutions were prepared by dilution into 10mM phosphate/150 mM NaCl 
buffer and filtered through 0.45 µm membrane filters prior to use. Samples were plated in 
triplicate in black walled 96-well plates at 30 µL/well to which 100 µL of 1x ThT working 
solution was added and allowed to react for 5 min at room temperature. The fluorescence 
intensity was measured using BioTek Nova plate reader with excitation at 440 nm and 
emission at 482 nm. 
Liquid Chromatography-Mass Spectrometry 
Antibody tryptic digests were prepared per manufacturer procedure from the low 
pH protein digestion kit (Promega, CAS # CS1895A01), designed to prevent non-
enzymatic protein modifications during digest. Antibody samples were denatured in 8 M 




incubated with Trypsin Gold and Lys-C (Promega) at 20:1:1 (w/w/w) ratio overnight at 
37°C. After digestion was complete, the reactions were acidified with trifluoroacetic acid. 
500 ng of each digested sample was analyzed by nano UPLC-MS/MS with a 
Proxeon EASY-nLC 1000 HPLC system interfaced to a ThermoFisher Q Exactive HF 
mass spectrometer. Peptides were loaded on a trapping column and eluted over a 
75 µm × 50 cm analytical column (Thermo Fisher P/N ES-803) at 300 nL/min by using a 
2-hour reverse phase gradient; both columns were packed with PepMap RSLC C18, 
2 µm resin (Thermo Scientific). The mass spectrometer was operated in data-
dependent mode, with MS and MS/MS performed in the Orbitrap at 70,000 and 17,500 
FWHM resolution, respectively. The 15 most abundant ions were selected for MS/MS. 
Data analysis for LC-MS/MS analysis of digested specimens was performed with 
Byonic search software (Protein Metrics Inc., San Carlos, CA, USA).394,395 In this 
instance, the search used the infliximab sequence. Identifications for peptide ions were 
made by matching the precursor (MS1) mass and expected fragment ion masses (MS2) 
to infliximab peptides. The search included variable modifications such as mono- and di-
oxidation on methionine and tryptophan, deamidation and ammonia loss from 
asparagine, and a wide range of N-linked glycans. 
Quantification of modifications relative to unmodified and other modified peptides 
was accomplished using the Byologic software (Protein Metrics), which uses a label-
free quantification approach with extracted ion chromatogram areas (XIC areas). This 
software automated the XIC extraction and data organization automatically from the 




Ion Mobility Mass Spectrometry 
Reconstituted antibody samples for native MS experiments were buffer 
exchanged into 100 mM ammonium acetate buffer using Micro Bio-Spin 30 columns 
(Bio-Rad, Hercules, CA) without further purification. Sample aliquots (∼7 µL) were 
analyzed by IM-MS on a quadrupole-ion mobility-time-of-flight mass spectrometer (Q-
IM-ToF MS) instrument (Synapt G2 HDMS, Waters, Milford, MA).396,397 Antibody ions 
were generated using a nESI source in the positive mode. Capillary voltages of 1.4 kV-
1.6 kV were applied, and the sampling cone was operated at 60 V. The trap traveling-
wave ion guide was pressurized to 3.4 × 10−2 mbar of argon gas. The traveling-wave ion 
mobility separator was operated at a pressure of ∼3.5 mbar and used a series of DC 
voltage waves (40 V wave height traveling at 600 m/s) to generate ion mobility 
separation. The ToF-MS was operated over the m/z range of 1000–10000 at a pressure 
of 1.7 × 10−6 mbar. 
Mass spectra were calibrated externally using a solution of cesium iodide 
(100 mg/mL) and processed with Masslynx V4.1 software (Waters, Milford, MA). Exact 
molecular masses of intact mAb samples were calculated by assigning the charge 
states based on the set that gives lowest standard deviation for a given average mass 
assignment.398,399 Relative dimer ratios were calculated from total ion counts of major 
charge states (30+ to 36+) compared with that of major monomer charge states (20+ to 






The binding of infliximab to FcγRIIIa was tested with biolayer interferometry using 
a BLITZ instrument (Fortebio, Menlo Park, CA). The procedure used here was adopted 
from the method reported previously.400,401 Protein G biosensor tips were used and the 
binding measurement was performed at 25°C. Infliximab samples at 4.6 µM (1 mg/mL) 
initial concentration in formulation buffer were diluted to 0.8 µM with PBS containing 
1 mg/mL casein as a blocking agent (kinetic buffer). Binding studies were performed as 
follows: First, the protein G biosensor tip was hydrated in PBS for 10 min and then 
incubated for 30 min in kinetic buffer. Next, an initial baseline (30 s) was established in 
the kinetics buffer and then the protein G biosensor tips were loaded (120 s) with 
infliximab samples at a concentration of 0.8 µM to a response level of ∼4 nm. A new 
baseline (240 s) was then established followed by the association (180 s) and 
dissociation (360 s) of FcγRIIIa measured by dipping the biosensor into solutions of 
FcγRIIIa and PBS kinetic buffer, respectively. The biosensor tips were regenerated as 
described previously400 after each assay cycle. To determine the dissociation constant 
(KD), a range of FcγRIIIa concentrations from 0.4 µM-3.2 µM was evaluated. Data 
generated from the binding of the receptor to infliximab were collected in triplicate for 
each incubation time point and product, lot and globally fitted to a 1:1 binding model 
using BLITZ Pro software. 
ELISA for TNF Binding 
 96-well ELISA plates (Nunc Maxisorp) were coated with 1 µg/mL TNF (R&D 
systems) in PBS (pH 7.4) overnight. The plates were washed for 4 cycles with PBS (pH 




room temperature with 1% bovine serum albumin (BSA) in PBS (pH 7.4) solution. The 
plates were washed again and incubated for 1 h at room temperature with infliximab 
standards (1 ng/mL to 100,000 ng/mL) and diluted samples of equal concentrations. All 
standard and sample dilutions were prepared in PBST-BSA (PBS (pH 7.4) containing 
0.02% Tween 80 and 1% BSA). The plates were once again washed and then 
incubated with 1000-fold dilution of AP-conjugated anti-human Fc IgG (Sigma-SKU: 
A9544) in PBST-BSA for 1 h at room temperature. The plate was then washed again to 
remove residual secondary antibody and incubated with p-nitrophenyl phosphate 
(pNPP) (Sigma) for 30 min at room temperature for color development. Absorbance at 
405 nm was then read using plate reader (Spectra Max M3, Molecular Devices). A 
standard curve was built using a sigmoidal fit and concentrations of diluted samples 
were calculated. The sample concentrations were divided by the initial unstressed 
Remicade® concentration to determine the relative TNF binding activity. 
Statistical Analysis 
Statistical analysis was performed using Prism 6 (Graphpad) suite. 2-way 
ANOVA hypothesis testing was performed using multiple comparisons relative to initial 
samples of Remicade® or Remsima™. Corrections for multiple comparisons were 








Protein Stress: Monomeric Changes and Particulate Formation 
For forced degradation studies, the powders of the 2 products were subjected to 
incubation at 40°C, at various humidity levels (dry to 97% relative humidity (RH)). A 
schematic of the study design is depicted in Fig. 3-1. Both Remsima™ (RC) and 
Remicade® (RS) were supplied as lyophilized powders in vials containing 100 mg of 
infliximab, 500 mg of sucrose, 0.5 mg Tween 80, and 8 mg phosphate buffer 
salts.387,392 Overall, the protein content of the powder cake was ∼16% (w/w). The 
powder melt temperatures, determined by modulated-differential scanning calorimetry 
(mDSC), were similar, with values of 135.8°C for Remicade® and 138.1°C for 
Remsima™. Product vials were opened, and powders were aliquoted into Eppendorf 
tubes and the open tubes were incubated for 0, 1, 2 or 4 weeks at 40°C and elevated 
humidity. At all incubation conditions, powders visually appeared moist, and those 
incubated at 97% RH deliquesced. 
Figure 3-1. Schematic of stress study design. Humidity/thermal stress of infliximab samples were 
performed by incubating the drug powders at 40ºC at different %RH for 0–4 weeks, followed by 




After incubation, water for injection (WFI) was added to the samples and levels of 
protein aggregation were examined by size-exclusion chromatography (SEC). Analysis 
revealed a time- and humidity-dependent loss of native monomer and formation of 
soluble aggregate. The kinetics of monomer loss were similar for the 2 products (Fig. 3-
2A,C). The rates of monomer loss were calculated using linear regression and are 
summarized in Table 1. The fastest rate of protein aggregation was observed at 97% 
RH with 0.42% monomer loss per day for Remicade® and 0.44% per day for 
Remsima™, and virtually no monomer loss was observed for the dry samples. Samples 
incubated for 4 weeks were further characterized by non-reducing SDS-PAGE (Fig. 3-
2B). The gel showed increased levels of aggregates with increasing relative humidity, 
but also the presence of mAb fragments not previously detected by SEC. Further 
characterization was performed using reducing SDS-PAGE (Fig. 3-2D). The absence of 
some aggregate bands after reduction suggests the aggregate formation was partially 
mediated by disulfide bonds. Jung et al. reported ∼0.12 free –SH mol/mol IgG for 




Particulate size for the reconstituted samples was measured using nanoparticle 
tracking analysis (NTA). Particulates from 50–350 nm were observed for both products, 
as shown in Fig. 3-3A,B. Remicade® had fewer observed particulates than Remsima™, 
both initially and after humidity stressing. Although the counts exceed several millions, 
the particle sizes measured were quite small, and, overall, the particulate counts 
showed large variability (Table 3-2). Further characterization of these samples was 
performed using nano-differential scanning calorimetry (nDSC)(Fig. 3-3C,D). The 3 
characteristic melt temperatures were determined (Tm1: 67°C, Tm2: 72°C, and Tm3: 
86°C) and were similar for the 2 products, in agreement with previously published 
values.136 No thermal shifts in the melt temperatures were observed for either product 
following stress; however, a decrease in overall heat capacity was noticed for the 
stressed samples. Since the amount of material was held constant, this suggests less 
energy is required for unfolding after stressing.  
Figure 3-2. (A) SEC-LC infliximab chromatograms over incubation at 97% RH/40ºC and (B) Kinetics of 
monomer loss. (n = 4, n ± SEM) Characterization by (C) SDS PAGE and (D) Reducing SDS PAGE of 









Table 3-2. Rates of monomer loss for RC/RS after incubation at various humidities/40ºC. 
Figure 3-3. (A) Nanoparticle tracking analysis and (B) DSC thermal melts of unstressed (light) and 




Additional forced degradation studies were performed to evaluate antibody stability 
in solution. Little to no change, as measured by SEC and ThT, was seen for protein 
samples incubated at 4-40°C over the course of 1 week. However, samples incubated at 
60°C showed rapid aggregation and precipitation. Follow on studies were performed at 
60°C with multiple lots of Remicade and Remsima incubated for up to 3 hours to establish 
lot-to-lot variability after thermal stressing for each product as well as to explore 
differences between two products. All samples were analyzed by SEC, ThT, and selected 
samples were analyzed by Nanosight (NTA) and LC-MS/MS after trypsin digest. Results 
from the different assays are summarized in Fig. 3-4. Nearly all the protein appeared to 
be aggregated after 1hr at 60°C as indicated by Fig. 3-4A,B. Following thermal stress, 
aggregate particle sizes were measured by DLS which yielded similar particles sizes for 
both products, but with wide size distributions. NTA was subsequently used to resolve 
smaller particle sizes (Fig. 3-4C). Several million particles less than 600 nm in size were 
observed for both products with Remicade having a broader particle size distribution than 
Remsima. LC-MS characterization (Fig. 3-4D-F) shows the propensity of a few sites for 
chemical modifications (deamidation at N392, N424 as well as increase in dioxidation at 
various W sites). Thermal stress at the high temperature of 60°C (near the protein melt 
temperatures as determined by nDSC) seems to induce protein unfolding that leads to 
rapid aggregation. In some instances we also observed simultaneous changes in 
chemical purity. Overall, due to the strong parallel between SEC and ThT results, thermal 




exposure rather than by chemically mediated process. Overall, the response of both 
products to thermal stress is similar, again reinforcing the biosimilarity of the products. 
Characterization of Protein Aggregates and Hydrolysis Products 
To augment SEC and SDS-PAGE analyses, unstressed and 97% RH/4-week 
incubated samples for both products were further characterized by ion mobility mass 
spectrometry (IM-MS). The IM-MS analysis is capable of examining antibodies under 
native conditions with minimal handling of samples compared with other MS-based 
methods. Relatively weak electric fields are used to separate gas-phase protein ions 
accordingly to their orientationally averaged collision cross sections (CCSs) and charge. 
IM-MS spectra displayed similar IM drift times for Remicade® and Remsima™ with 
discrete positions in drift time vs. m/z space for antibody fragments, monomers, dimers, 
and trimers (Fig. 3-5). The IM-MS results suggested that small initial levels of antibody 
impurities increase significantly after humidity and temperature stressing (Table 3-3). 
Figure 3-4. Characterization of RC (blue) and RS (orange) incubated at 60ºC. (A) Kinetics of 
monomer (SEC-LC) and (B) ThT fluorescence. (C) NTA analysis after 2 hrs of incubation. LC-




For example, the presence of dimer and trimer protein aggregates, as well as 50 and 
100 kDa antibody fragments, were observed in stressed samples. Appearance of these 
species was evident from the different drift times relative to protein monomer drift time, 
as observed in IM-MS spectra (Fig. 3-5). While the initial levels of aggregates were 
slightly higher for Remsima™ (0.35% by SEC, 2.0% by IM-MS) than for Remicade® 
(0.08% by SEC, 0.8% by IM-MS), these differences did not result in faster aggregation 
upon stress for Remsima™. The large initial dimer differences between the 2 products 
as measured by IM-MS may be attributed to method variability and should be 
interpreted with caution, as only 2 batches of each product were analyzed. The levels of 
dimer were similar in stressed samples for Remsima™ (12.4% by SEC and 3.5% by IM-
MS) and Remicade® (12.7% by SEC and 3.0% by IM-MS), and the presence of trimers 
was detected at 0.1% in both products by IM-MS.  
The levels of dimers in stressed samples measured by IM-MS appear to be lower 
than the levels measured by SEC, indicating that possibly some of the newly formed 
dimers dissociate during mass spectrometry analysis or during sample preparation, e.g., 
buffer exchange before mass analysis. Prominent fragment sizes of 50 and 100 kDa 
were observed by IM-MS and may be antibody fragments corresponding to 1 heavy 
Table 3-3 Impurity profiles of RC and RS before and after 4 weeks of incubation at 97% RH/40ºC (n = 2, 




chain or 2 linked heavy chains, respectively, whereas fragments of 125 kDa by SDS 
PAGE suggest the loss of one light chain from the mAb. These modifications confirm 
the susceptibility of infliximab to undergo inter-chain disulfide rearrangements upon 
humidity stressing. While the levels of protein fragments appear to be higher for 
Remsima™ than for Remicade® following forced degradation, there is high variability in 
the measurements and a limited number of samples were available for analysis. 
Overall, while a significant degree of infliximab aggregation and hydrolysis was 
observed after the 4-week stress, there were no statistically significant differences in the 
levels of impurities between the 2 stressed products.  
Figure 3-5 . IM-MS spectra and corresponding mass to charge spectrograms of unstressed (A) RC and 
(B) RS before incubation and (C) RC and (D) RS after 4 weeks incubation at 97% RH/ 40ºC. Fragment, 





To better understand the structural changes induced by humidity stressing, 
selected samples were probed using bulk-averaging spectroscopic techniques. Intrinsic 
fluorescence and near UV circular dichroism (CD; 250–320 nm) were used to gather 
information about the tertiary structure, while far UV CD (190–250 nm) measurements 
were used to probe the secondary structure. Intrinsic fluorescence examines changes in 
the local environment surrounding aromatic amino acids and it assesses how this local 
hydrophobicity alters the emission profile upon protein stress.402 The intrinsic 
fluorescence curves for Remicade® and Remsima™ samples incubated for 0, 2 and 
4 weeks at 97% RH are shown in Fig. 3-6A,B. Both products had a maximum intensity 
at 335 nm and they showed no substantial differences upon humidity stressing, apart 
from a slight decrease in maximum relative fluorescence intensity. Linear drop-offs in 
the maximum intensity (λ335) are observed with increasing incubation times, suggestive 
of partial unfolding, aggregation, or monomer loss. Our results, which show high 
homology between the 2 products, also demonstrate comparable intrinsic fluorescence 
profiles to published results for other IgG1s.160,403,404 
Near UV and Far UV CD spectra were collected to confirm the intrinsic 
fluorescence findings, as shown in Fig. 3-6C,D. The Remicade® spectra did not change 
substantially with the increased duration of protein incubation. The Remsima™ samples 
showed little change over 2 weeks but showed a large deviation for the 4-week sample 
at 250–280 nm not observed for Remicade®. The initial near UV spectrums look similar 
to published results for infliximab.136 A small shift in absorbance was observed at the 




similar to the earlier drops in the intrinsic fluorescent spectra. Regarding the deviation in 
the near UV spectrum between 250 nm and 280 nm in the 4-week Remsima™ sample, 
the spectral pattern suggests a change in the sulfide linkage profile for this sample, in 
agreement with the earlier findings from IM-MS and SDS-PAGE. It is unclear, however, 
why similar shifts were not observed for other samples, which should have also 
undergone similar disulfide rearrangements as suggested by previous data. 
Figure 3-6. Biophysical characterization of humidity stressed samples of RC (solid) and RS (dashed). 





We next assessed the far UV CD to capture any secondary structural changes 
that might have occurred due to humidity stressing. Far UV CD from 190 nm to 250 nm 
has been used extensively to study secondary structure of proteins and antibodies.405–
407 As shown in Fig. 3-6E,F, the far UV CD spectra showed considerable similarity 
between the 2 products. In addition, Remicade® samples displayed small time-
dependent deviations in their secondary structure. By contrast, Remsima™ samples 
showed a slight increase in positive signal at 218 nm, suggesting a greater anti-parallel 
β structure. Yet, the overall shapes of spectra were similar for the 2 products, indicating 
that secondary structural differences between Remicade® and Remsima™ following a 
4-week incubation were negligible. The variability of native protein concentration in 
stressed samples somewhat limits the utility of these intrinsically low resolution 
spectroscopic methods for biosimilarity characterization. 
Individual Amino Acid Modifications 
To further characterize how humidity stress leads to chemical modifications of 
the individual amino acids, the proteins were enzymatically digested and analyzed by 
LC-MS. As shown earlier by LC-MS, both products exhibit similar but significant 
degrees of oxidation and deamidation, as well as rather different distributions of N-
linked glycans.7 Here we applied LC-MS methodology to examine whether initial small 
differences in chemical modifications can be amplified upon stress, as well as to identify 
infliximab's “hot spots,” i.e., the amino acid residues easily susceptible to modifications 




Chemical modifications of the stressed samples were analyzed by LC-MS and 
depicted in Fig. 3-7. The asparagine deamidation levels were initially similar for 
Remsima™ and Remicade® at light chain residues N-137 and N-158, and at heavy 
chain residues N-31, N-57, N-318, N-364, N-387, N-392, and N-424. After humidity 
stress, deamidation levels for both Remsima™ and Remicade® increased at all 
measured residues (Fig. 3-7A). The highest levels of deamidation after 4-week 
incubations were observed for LC N-158 (7.5%), HC N-57 (18–19%) and HC-N-392 
(10–11%). The deamidation of conserved Asn 384 (N-387, 384+3 due to different 
numbering schemes) and 389 (N-392), located in the Fc region, that is responsible for 
antibody binding to Fcγ and neonatal Fc (FcRn) receptors, might be expected to be 
significant. While we observed significant increases in deamidation of N-387 and N-392 
residues, the extent of deamidation was similar between Remicade® and Remsima™. It 
also has been shown for other antibodies that deamidation of Fc region residues did not 
significantly alter Fc receptor binding.128,129,390,408 The Fc receptor binding is primarily 
dictated by glycosylation of mAb, specifically the levels of afucosylated species.  
  
Figure 3-7. LC-MS/MS analysis of chemical modifications over the course of incubation at 97% RH/40ºC 





In contrast, deamidation of HC N-57 could be significant due to the residue's 
location in the complementarity-determining region (CDR); thus, deamidation of HC-N-
57 could potentially reduce infliximab's binding to TNF. Other antibodies have been 
shown to exhibit reduced binding abilities to their respective antigens upon chemical 
modifications of amino acids in the CDR.103,390,408 Interestingly, while deamidation 
appears to increase with the duration of incubation for some asparagine residues (N57, 
N318, and N392), others exhibit the same deamidation levels after 2 and 4 weeks. This 
provides information regarding the conformational flexibility of the mAbs and the 
propensity and accessibility of select residues to deamidation. Overall, levels of 
deamidation appear to be very similar between Remicade® and Remsima™ products 
both initially and following stressed degradation. 
The levels of initial and stress-induced methionine oxidation were analyzed as 
well (Fig. 6B). Our results indicate significant initial oxidation levels for M-55 at 6.3% 
(LC) and M-18 (∼7%), M-34 (∼13%), M-85 (8.2%), M-255 (∼12%) and M-431 (∼4%) on 
the heavy chain. However, oxidation levels appeared to be unchanged following forced 
degradation. Overall, the levels of oxidation are very similar for the 2 products. The 
oxidation of methionine residues in the Fc region of IgG1 (M-252 and M-431) is known 
to reduce binding to FcRn and decrease circulation in vivo.409 In addition, oxidation of 
these methionine residues leads to reduced IgG1 binding to Protein-A column during 
purification.128,129,390,408 While we also observe oxidation of the critical methionine 
residues HC M-255 (252+3) and HC M-431 (428+3), the levels are similar in the 2 




The results of our exploratory infliximab solution thermal stability study indicated 
significantly increased HC M-255 oxidation levels after incubation at 60°C (Fig. S1D-E), 
highlighting the importance of this residue as a “hot-spot” for infliximab degradation 
pathways. In addition, increases in tryptophan di-oxidation were observed in heat-
stressed protein solutions, specifically the di-oxidation of HC W-33, W-47 and W-161, 
which increased from <0.5% to ∼2–4%. We also observed an increase in deamidation, 
especially for HC N-387, N-392 and N-424. 
In addition to oxidation and deamidation, we examined conserved N-
glycosylation of the Fc domain by LC-MS. Glycosylation occurs during recombinant 
production of infliximab and is defined to a large degree by the specific cell line clone as 
well as cell culture conditions.410 Both products were produced using murine hybridoma 
cell line Sp2/0, but using different infliximab expressing clones generated by the 
innovator and biosimilar companies.300 8 Thus, it is not surprising that a biosimilar 
product like Remsima™ exhibits different distributions of glycans relative to the 
reference product Remicade®.43,300,388 We also confirmed initial differences in glycan 
distribution, with G0F, G0F-Man, G0F-Man(3) and G0F-Man(1) being more abundant in 
Remicade® while G1F, G2F and G2 more prevalent in Remsima™ (Fig. 6C). These 
initial differences are important, as it appears that overall levels of mannose and 
afucosylated glycans are higher in Remicade® than in Remsima™, and this is known to 
affect Fc receptor binding, antibody dependent cell-mediated cytotoxicity (ADCC), 
circulation time and immunogenicity.411 We also observed that glycan distribution 
remained virtually unchanged for both Remicade® and Remsima™, as expected. 




unlikely that glycosylation could be altered during stressed stability studies apart from 
possible selective aggregation/degradation of a specific glycan type. 
In Vitro Efficacy 
In addition to the analytical characterization of the humidity stressed samples, we 
also performed in vitro bioactivity assays to gauge how stressing affects infliximab's 
abilities to bind TNF and FcγRIIIa (Fig. 3-8). We expected that stressed-induced 
individual amino acid modification in the CDR could reduce infliximab's binding to TNF, 
while modification of the Fc domain could alter FcγRIIIa interactions. In addition, the 
reduction of intact infliximab monomer content over the duration of the forced 
degradation study could lead to further reduction in antigen and receptor binding.  
According to regulatory filings, Remicade® and Remsima™ exhibit similar initial 
ability to bind and neutralize TNF.43,300 The 90% confidence interval for the mean 
difference between Remicade® and Remsima™ TNF binding affinity measured by 
ELISA falls entirely within the equivalence margin. 346 Our measurements, derived from 
only 2 lots for each product, indicated that the TNF binding affinity was slightly higher for 
Figure 3-8 (A) TNF-α binding (measured by ELISA) (B) FcγRIIIa binding (measured by BLITZ) (n = 2, 




Remsima™, at 111.7% of the initial Remicade® value, but this result was not statistically 
significant (Fig. 3-9A). Following 4 weeks of forced degradation, TNF neutralization 
decreased to 81.8% (Remicade®) and 77.2% (Remsima™) of the initial value for 
unstressed Remicade® standard. This decrease could be attributed to increased 
deamidation levels of HC-N-57 or reduced infliximab monomer content or both. 
However, there was no statistically significant difference in TNF binding affinity between 
2 stressed products at the corresponding time points. 
The differences in FcγRIIIa binding corresponding to the lower levels of 
afucosylation for Remsima™ relative to Remicade® were reported previously.388 In the 
regulatory filing, decreased afucosylation was reported, and corresponded to a 20% 
lower binding efficiency to FcγRIIIa and 20% lowered ADCC for Remsima™ relative to 
Remicade®.346 The initial unstressed samples of Remicade® showed tighter binding to 
FcγRIIIa relative to Remsima™ with the respective KD of 173 ± 56 nM and 368 ± 
160 nM, as measured by biolayer interferometry (Fig. 3-9B). The receptor binding 
progressively weakened following stress degradation of the 2 products, and the 
KD increased to 545 ± 117 nM for Remicade® and 680 ± 22 nM for Remsima™ after 
4 weeks at elevated humidity and temperature. Since no significant changes in 
glycosylation between the 2 products were detected upon incubation, the reduction in 
Fc receptor binding is likely attributed to the progressive increase in aggregation and 
fragmentation of the 2 antibodies, in conjunction with the chemical modifications, thus 
reducing the total amount of bioactive monomer available to bind receptors. 
Additionally, the initial differences in Fc binding between the 2 products appear to 




glycosylation patterns for bioactivity. Overall, no statistically significant differences in 
FcγRIIIa binding were observed throughout the entire study, which was possibly due to 
the small number of lots tested (n = 2). 
 Discussion 
In this study, humidity- and temperature-induced forced degradation was used to 
analytically compare a biosimilar mAb, Remsima™, with its reference product, 
Remicade®. Despite the minor differences in initial product profiles (glycosylation 
pattern, levels of dimer and basic variants), as well as differences in the manufacturing 
processes of 2 mAbs, the 2 products behaved remarkably similarly in the forced 
degradation studies.43,136,300 Very similar rates of degradation, along with similar types 
and levels of impurities were detected in the 2 stressed products. Hence, for products 
with high analytical similarity and identical formulations, such as Remsima™ and 
Remicade®, the degradation mechanisms appear to be defined primarily by protein 
sequence and structure rather than by minor initial product differences. However, other 
biosimilar products may be formulated differently or produced in different expression 
systems compared with their reference products, both potentially leading to greater 
product differences and varying mechanisms of protein instability in forced degradation 
studies.139,29 
Our results revealed the main infliximab degradation products to be protein 
aggregates and antibody fragments of 50 and 100 kDa. The rate of monomer loss was 
nearly identical for the 2 products under the various humidities tested, and higher initial 




levels of formed aggregates and antibody fragments varied slightly when measured by 
SDS-PAGE, IM-MS and SEC. An increase in the level of subvisible particulates was 
observed for both products by NTA after stressing. Each analytical method has inherent 
limitations due to variations in the sample handling, e.g., concentration/dilution, buffer 
exchange, mixing with gel loading buffer and binding to column matrix, which is known 
to affect aggregate before the detection.412 Hence, use of orthogonal methods allows for 
a more complete picture of protein aggregation and hydrolysis. 
Structural changes in the 2 products were compared spectroscopically. The near- 
and far-UV spectral results for the initial samples are in agreement with the published 
results for the native protein and small changes in spectra were observed in stressed 
samples.136 No thermal shifts were observed in stressed samples by nDSC, but lower 
enthalpy indicated minimal structural changes. Further analysis suggests these 
products slightly unfold, but undergo significant deamidation at specific “hot spots” upon 
stressing, as measured by LC-MS. Overall, structural and chemical modifications were 
comparable between the products. The TNF neutralizing ability of both antibodies was 
reduced significantly upon stress, by ∼20–30% relative to the unstressed protein levels. 
This reduction could be attributed to individual amino acids modifications in the CDR 
domain (LC-M-55, HC-M-34, HC-N-31 and HC-N-57), as well as to the decrease in 
functional protein monomer content. Nonetheless, regardless of mechanism, the 2 
products exhibited a similar magnitude of reduction in TNF binding. Additionally, post-
stress FcγRIIIa binding was reduced significantly for both products, by 2–3-fold, with 
slightly larger mean decreases for Remsima™ binding at each time point. However, 




products. Interestingly, using a larger number of lots for Remicade® and Remsima™, 
we showed that the level of afucosylation was significantly higher in unstressed 
Remicade, which corresponded to stronger FcγRIIIa binding relative to Remsima™. 
Such differences in glycosylation, along with the reduction in FcγRIIIa binding and 
ADCC were reported in the regulatory filings for Remsima™, resulting in the deferral of 
biosimilar approval for inflammatory bowel disease indications by Health 
Canada.43,300,413,414 While glycosylation differences between products did not change 
following forced degradation, the FcγRIIIa binding decreased similarly for the 2 
products. A several fold reduction in the FcγRIIIa binding after forced degradation could 
be attributed to individual amino acid modifications in the Fc domain, as well as to 
extensive aggregation and hydrolysis of the 2 mAbs. However, this finding shows that 
forced degradation could mute rather than amplify initial differences between biosimilar 
and reference product, which was surprising and contradictory to the initial expectations 
for this study. 
Stress testing is often used to identify instabilities in proteins, select optimal 
formulations to reduce protein degradation during stability testing, and to define shelf-
life and storage conditions. Antibodies, particularly IgG1s, have been stressed in a 
variety of ways, including thermally, physically (e.g., stirring, shaking), and chemically 
(e.g., oxidation, pH).160,415 Overall, different mechanisms of stressing have yielded 
different by-products; however, in general, IgG1s are prone to aggregation and 
chemical modification of several conserved residues identified as “hot-spots.”390 Most 
stress conditions lead to aggregate formation, either insoluble, soluble, or 




tertiary features of mAbs that may initiate aggregation.403,406 Chemical stressing has 
also identified several oxidation hot-spots on mAbs and accessibility of various 
residues.160,390,416 Aggregates formed via different stressors are heterogeneous and 
express differing immunogenic patterns test in various immunogenicity 
models.160,417,418 In general, physical stressing (thermal, agitation) leads to greater 
particulate formation and yields a stronger immune response than chemically stressed 
samples. 377,378 Stress-induced particulate formation highlights a need for characterizing 
how process parameters, excipients and formulation differences in biosimilars affect 
protein aggregation, as they may ultimately affect product immunogenicity and safety. 
To demonstrate biosimilarity, the 2 products should have no “clinically 
meaningful” differences. Thus, comparison of lot release data for biosimilar and 
reference products are the most critical for determining biosimilarity. However, the rates 
and mechanisms of degradation of reference and biosimilar products can also be 
compared during forced degradation studies. These comparisons are particularly useful 
if the biosimilar is formulated differently compared with the reference product, as it could 
result in new types of degradation products observed in the biosimilar that are not 
present in the reference product. The presence of new types of degradation products 
raises additional questions if these degradants could potentially affect product efficacy 
and safety. 
While forced degradation studies allow rapid generation of a large volume of 
analytical comparability data, the mechanism of protein instability and type of 




conditions of forced degradation studies are more extreme than the actual stresses that 
product vials are exposed to during transport, storage, and clinical administration. In this 
study, to accelerate protein degradation, the vials were opened, and products were 
exposed to much higher temperatures and humidity than the environment inside sealed 
and refrigerated vials. For traditional biosimilarity comparisons the analyses are 
performed using several lots of each product. In our constrained study, only 2 lots of 
each product were subjected to the forced degradation, which limits our ability to 
perform rigorous statistical analysis. We observed large deviations in product 
modifications in the stressed samples, which, in addition to limited sample size, may 
also arise from the heterogeneous nature of degradant formation, especially at the 
primary chemical levels. Due to the limited amount of protein, we did not examine the 
effects of oxidative, mechanical, and chemical stress on reconstituted infliximab 
solutions for every time point. Furthermore, we have not characterized the type, shapes, 
and sizes of formed protein aggregates and have not examined the levels of protein 
glycation in this study, which may be of interest for immunogenicity characterizations. 
The immunogenic propensity of biologics is a key safety parameter identified by 
regulatory agencies. To date, several studies have used a variety of stresses to form 
immunogenic products, and characterized their immunogenicity in various in vitro and in 
vivo models.160,417,418 General correlations between characteristics of stressed protein 
(type, shape and size of protein aggregates) and the immunogenicity of these 
degradation products were developed.390,415–418 Thus, forced degradation could provide 
valuable predictive data regarding the immunogenic propensity of the biosimilar product, 




challenge in applying this stress testing strategy is the lack of universal 
conditions/guidelines to perform the studies, which leads to different setup conditions 
and, thus, difficulty in extrapolating results. Ideally, the solution would be to adopt 
guidelines to perform these tests, but this is confounded by the diverse nature of 
biotherapeutics, each of which may display different behaviors. Given these concerns, it 
is recommended that stress studies be designed with specific ends in mind, and that 
several orthogonal robust analytical techniques be used to ensure confidence in the 
final outcomes. 
Biosimilar approvals are poised to bring substantial positive change to healthcare 
yet establishing biosimilarity is challenging. Forced degradation studies provide a 
unique approach to examine the appearance of any minor differences that may have 
clinical safety, immunogenicity, and efficacy implications. In this study, we used thermal 
and humidity stress testing on both reference, Remicade®, and biosimilar, Remsima™, 
infliximab products. Our results show similar levels of aggregate formation, structural 
variation, and chemical modifications to support the notion that the products are 
biosimilar. We anticipate stress testing will be used widely for biosimilar assessment as 
patents for more biologic products expire and new biosimilar products permeate the 




Chapter 4: Disulfide Shuffling Comparability of Originator/Biosimilar mAb Pairs 
 Abstract 
Disulfide bonds play a critical role in maintaining the structure, stability, and 
function of monoclonal antibodies (mAbs). The modification of disulfide bonds can result 
in altered safety, efficacy and immunogenicity. Since the regulatory approval of a 
biosimilar mAb requires extensive characterization, it is important to understand the 
sights of potential disulfide shuffling and the formation of potentially immunogenic 
impurities. 
In the first part of this project, tandem mass spectrometry (LC-MS/MS) was used 
to compare disulfide bonding for an originator/biosimilar infliximab, rituximab and 
bevacizumab pairs, where LC-MS/MS outputs were analyzed using a Protein Metrics’ 
Byonic™ and Byologic® workflow, which allows for the detection, identification, 
quantification and comparison of expected disulfide bonds and related impurities 
(shuffled disulfide and trisulfide bonds). The relative contribution of shuffled and 
trisulfide bonds were found to be higher for biosimilar infliximab and biosimilar 
bevacizumab than their respective originators. On the other hand, for rituximab, the 
relative contribution of shuffling for the biosimilar was identical to that seen for originator 
and no trisulfides were detected. These differences of disulfide shuffling would seem to 





In the second part of this project, originator and biosimilar rituximab and 
bevacizumab were subject to forced degradation, where these pairs were incubated at 
37ºC for 4 weeks at. LC-MS/MS was used to compare changes of shuffled disulfide and 
trisulfide bonds over the course of incubation. The relative contribution of shuffled 
disulfide bonds for originator/biosimilar rituximab were similar over the course of 
incubation. The relative contribution of disulfide shuffling for originator and biosimilar 
bevacizumab not only started with higher initial levels of disulfide shuffling and trisulfide 
bonding but also had greater extents of shuffling over incubation. In addition, the 
relative contribution of disulfide shuffling for biosimilar bevacizumab was greater than 
the originator. Physical degradant characterization (SDS PAGE and SEC) was then 
used to assess and confirm the relationship of protein degradation to disulfide shuffling. 
It was observed that bevacizumab was more prone to both physical degradation and 
disulfide shuffling than rituximab, where again the biosimilar bevacizumab had more 
initial degradation than the originator. Lastly, free thiol content was analyzed. Free thiol, 
while appearing greater for rituximab than bevacizumab, appeared to be related to less 
disulfide shuffling and less physical degradation, whereby free thiols were detected 
upon exposure over incubation. For bevacizumab, free thiol content also appeared 
related. Though less free thiols were detected, this is likely due to their participation in 
disulfide shuffling and degradation that was greater than that observed for rituximab. 
 Introduction 
Immunoglobulin Gs (IgGs) are comprised of 4 subtypes, IgG1-4, and are 
differentiated by the varied number and locations of their disulfide bonds.419,420 Disulfide 




subtypes. The studied infliximab, rituximab and bevacizumab originator/biosimilar pairs 
are IgG1s, the largest IgG subtype for currently marketed products.421 The three studied 
mAbs neutralize different antigens, including TNF-α (infliximab), VEGF (bevaciumab) 
and CD-20 (Rituximab). Infliximab and rituximab also rely on IgG’s crystallizable 
fragment (Fc) domain interaction with target effector (immune) cells for their therapeutic 
activity through antibody-dependent cellular cytotoxicity (ADCC).422 Another minor MOA 
that follows antigen-binding is the downstream complement cascade called complement 
dependent cytotoxicity (CDC); however, ADCC is more commonly understood to play 
the main role in therapeutic effect.422 
Formation of shuffled disulfide bonds can lead to structural changes, which, in 
turn, can result in function changes such as reduced antigen binding (a potential 
efficacy concern) and formation of misfolded/aggregated mAbs (a potential 
immunogenicity concern). It is important to recognize that modifications of a protein’s 
underlying structural backbone do occur and can result in functional changes,137,420,423.  
Therefore, characterization of whether disulfide bonding within an IgG is retained (in its 
“expected” form) or has been modified can be a useful way to deduce whether protein 





IgG1 Structure: Disulfide Bonds 
Disulfide bonds are covalently formed between the thiol groups of two cysteine 
amino acid residues in a mAb. Not only do they contribute to protein stability, but also 
dictate protein folding during translation.424 Disulfide bonds can occur either within HCs 
and LCs (intra-chain), between the HC and LC (inter-chain) of a mAb. Hinge region 
disulfide bonds are located between the Fab and Fc domains and occur between the 
two HCs (inter-chain). The IgG1 subtype has 12 intra-chain disulfide bonds and 4 inter-
chain disulfide bonds.419 There are two inter-chain disulfide bonds between the LCs and 
HCs, and two between the HCs (hinge region). There are two intra-chain disulfide 
bonds within each LC and four intra-chain disulfide bonds within each HC. Intra-chain 
disulfide bonds have been suggested to be responsible for the stabilization of tertiary 
structure while inter-chain disulfide bonds, which are more solvent accessible and 
susceptible to reduction, have been attributed to the stabilization of quaternary 
structure.425 All together, these 16 disulfide bonds are what we consider to be 
“expected” bonds and will be referred to as such for the remainder of this presentation. 
Methods of Disulfide Bond Characterization 
The standard techniques for disulfide bond characterization include a number of 
variations of liquid chromatography coupled to mass spectrometry (LC-MS). In “bottom-
up” MS approaches, a large protein is digested into smaller peptide segments by 
digestion enzymes, which are then separated by LC prior to MS/MS analysis, a 
technique that has been implemented in several previous studies to detect, identify, 
quantify and compare expected disulfide bonds and related impurities in 




characterized other chemical impurities through the use of reducing trypsin digestion, 
non-reducing trypsin digestions were used to prevent disulfide bond cleavage.  
Disulfide Bond Shuffling 
Disulfide shuffling (thiol-disulfide interchange) has been commonly suggested 
and been understood to occur as a function of free thiol levels. When deprotonated, 
thiols form a highly reactive thiolate anion that can attack the sulfur of a disulfide moiety 
through SN2 type nucleophilic reactions.113–116 Though not expected to occur as a result 
of high process control, previous studies have developed methods to detect small 
amounts of free thiols that can exist across recombinant subtypes and potentially serve 
as sources of disulfide shuffling.427,428 Other studies have shown that disulfide bond 
shuffling can trigger IgG’s aggregation pathway and result in the loss of stability, 
potency and activity (CDC and ADCC).115,429–433, 
Trisulfide Bonding 
The formation of trisulfide bonds, although found in all IgG subtypes, is less 
studied as it is a relatively rare modification.119 Resulting from a hypothesized redox 
reaction with excess dissolved hydrogen sulfide (H2S) in cell culture, trisulfides are 
thought to be formed by the insertion of a sulfur between two cysteines during 
fermentation.119,434,435 However, trisulfides have neither been shown to reduce antigen 
binding nor impact the stability of proteins, both in vitro and in vivo.119,436 Another study 
investigated the potential structural impact of trisulfide bonding in mAbs when 
developing antibody-drug conjugates (ADCs) and suggested precautionary monitoring 
of such modifications during development.437,438 Again, while there are some studies 




have a limited impact on stability or functionality, though their presence may indicate an 
underlying process variability between innovator/biosimilar mAb pairs.119 
 Methods 
MAb Sample Preparation/Stress Study Setup 
Originator and biosimilar samples of infliximab, rituximab and bevacizumab 
samples were acquired. Originator/biosimilar infliximab were supplied as lyophilized 
powders and were reconstituted using pure water for injection (WFI)(ThermoHyClone) 
to a concentration of 10 mg/mL as per the digest kit specifications. Originator/biosimilar 
rituximab were supplied as an aqueous formulation at a concentration of 10 mg/mL. 
Originator/biosimilar bevacizumab were supplied as an aqueous formulation at a 
concentration of 25 mg/mL that was then diluted to 10 mg/mL using pure WFI. All 
chemical reagents were of analytical grade or purer and were purchased from 
commercial suppliers. Only originator and biosimilar rituximab and bevacizumab pairs 
were subject to forced degradation at 37°C for up to 4 weeks. 
Trypsin Digestion (Infliximab) 
Originator and biosimilar infliximab samples were prepared at a concentration of 
1 were digested at pH 5.6 using Promega’s AccuMAP Low pH Protein Digestion Kits 
utilizing their non-reducing protocol to avoid disulfide bond cleavage (Promega, CAS # 
CS1895A01), which was generously provided.439,440 This digest is referred to as “pH 5”. 
Prior to digestion, antibody samples (5 μL) were denatured by a 9M Urea/AccuMAP 
denaturing solution (42 μL). Free cysteines were then blocked by mixing the denatured 
samples with 200 mM NEM (2 μL) and incubating for 30 minutes at 37°C. Pre-digestion 




C (25 μL) and incubating for 1 hour at 37°C. Digestion was completed after an addition 
of AccuMAP 10X Reaction Buffer (10 μL) and AccuMAP Low pH Resistant rLys-C that 
had been diluted with NANOpure water (25/51 μL). The reaction was terminated upon 
the addition of TFA (17 μL). The pH was assessed to ensure termination of the reaction. 
Samples were stored at -20°C prior to analysis. These samples were then subjected to 
clean up/purification using SepPak C18 Plus light cartridges (Waters, SKU WAT051910) 
prior to injection onto LC-MS/MS.  
Trypsin Digestion (Rituximab/Bevacizumab) 
 Originator and biosimilar rituximab and bevacizumab were also digested at pH 
5.6 using Promega’s AccuMAPTM Low pH Protein Digestion Kit utilizing their non-
reducing protocol to avoid disulfide bond cleavage (Promega, CAS # CS1895A01), 
which was generously provided. For this section, mAb digestion was modified from 
Promega’s provided protocol to account for use of a PCR plate on an Agilent AssayMAP 
Bravo robot platform. Use of the Agilent AssayMAP Bravo platform and LC-MS/MS 
instrumentation was thanks to MS Bioworks (Ann Arbor). Solutions of 200 mM NEM, 50 
mM acetic acid, trypsin diluent (CaCl2 in acetic acid), “Platinum Trypsin” and termination 
solution (20%TFA) were prepared prior to digestion. 3 µL of 10 mg/mL mAb was added 
to the PCR plate and then combined with 8M AccuMAPTM Denaturing Solution, low pH 
AccuMAPTM reaction buffer and NEM, which was then incubated at 37ºC for 30 minutes 
in a water bath. Samples were then mixed with Lys-C and incubated at 37ºC for 2.5 
hours and then digested with a combination of low pH reaction buffer, lys-C and Trypsin 
Platinum. This mixture was then incubated overnight at 37ºC in a water bath. 20% TFA 






Digested antibody samples (500 ng) were analyzed by nano UPLC-MS/MS with 
a Proxeon EASY-nLC 1000 HPLC system interfaced to a ThermoFisher Q Exactive HF 
mass spectrometer. Peptides were loaded on a trapping column and eluted over a 75 
μm x 50 cm analytical column (Thermo Fisher P/N ES803) at 300 nL/min with a 2-hour 
reverse phase gradient; both columns were packed with PepMap RSLC C18, 2 mm 
resin (Thermo Scientific). The mass spectrometer was operated in data-dependent 
mode, with MS and MS/MS performed in the Orbitrap at 70,000 and 17,500 FWHM 
resolution, respectively. The most abundant ions were selected for MS/MS. 
LC-MS/MS (Rituximab/Bevacizumab) 
 Data Dependent Acquisition (DDA) experiments were carried out using half of 
each enriched sample by nano LC-MS/MS using a Waters M-Class system interfaced to 
a ThermoFisher Fusion Lumos mass spectrometer. Peptides were loaded on a trapping 
column and eluted over a 75 μm analytical column at 350 nL/min with a 30-minute 
reverse phase gradient; both columns were packed with Luna C18 resin (Phenomenex). 
The mass spectrometer was operated in a combined data dependent HCD mode, with 
MS and MS/MS performed in the Orbitrap at 60,000 FWHM resolution and 15,000 
FWHM resolution, respectively. The instrument was run with a 3s cycle for MS and 
MS/MS. DDA data was processed in ByonicTM with a 10 ppm parent mass tolerance, 
0.02 Da fragment mass error tolerance. Disulfide bonds and related impurities were 




disulfide and trisulfide bonds and normalized contribution, relative to the respective XIC 
AUC total. Trisulfides were reported as XIC AUCs when comparing pH. 
Byonic™/Byologic® Workflow 
Analysis of LC-MS/MS outputs were identified, quantified and compared for 
expected disulfide, shuffled disulfide and trisulfide bonds by a Protein Metric workflow 
that is explained in previous publications.394 
Gel Electrophoresis 
 Originator/biosimilar rituximab and bevacizumab pairs were first qualitatively 
investigated for physical degradation by SDS-PAGE gels. Gels were optimized to find a 
balance between the visualization of minor components and the ability to avoid well 
overloading (data not shown). To do so, mAb samples were diluted to approximately 10 
mg/mL and then further diluted to lower final concentrations ranging from 0.1-5 mg/mL. 
To prepare these final concentrations, we combined 5 µL of Loading Buffer (Thermo) to 
15 µL of mAb sample (a 1:3 ratio). These samples, along with the 10uL of HiMark Pre-
stained Protein Standard ladder (Thermo), were loaded onto 15 well 3-8% NuPAGE 
gels. Final mAb concentrations of 0.25 and 0.4 mg/mL were chosen for analysis of 
mAbs at different incubation time points and run at 150V for 1 hour. Gels were stained 
for 1 hour using SimplyBlue SafeStain (Thermo), cleaned with water, imaged and 
analyzed for relative component content using a Fluorchem M imager (ProteinSimple). 
Size Exclusion Chromatography 
Originator/biosimilar rituximab and bevacizumab pairs were investigated for 
physical degradation by SEC on a Waters UPLC BEH450 SEC column (2.5µm, 4.6 x 




interfaced with a 2489 UV/Vis detector. MAb samples were diluted with LC-MS grade 
water, from concentrations of approximately 10 mg/mL down to concentrations of 
approximately 1 mg/mL as confirmed by NanoDrop. The 1 mg/mL samples were 
injected onto the column at an injection volume of 10 µL. Samples were isocratically 
delivered with a pH 7.4 1x PBS mobile phase at a flow rate of 0.4 mL/min over 10 
minutes. MAb samples were detected and compared via UV absorbance 
chromatograms that were extracted at 280 nm. 
Free Thiol Analysis 
Free thiols were analyzed through the use of a thiol-reactive probe, BODIPYTM 
FL N-(2-aminoethyl) maleimide (ThermoFisher Scientific). This probe is referred to as 
bodipy maleimide throughout the rest of the chapter. Bodipy maleimide stock solutions 
were prepared through reconstitution in DMSO at a concentration of 1 mg/mL and then 
then diluted to 0.2 mg/mL with 8M GuCl. Bodipy maleimide stock solutions (and any 
resulting solutions) were wrapped in aluminum foil to prevent light exposure. Stock 
solutions were kept at -20°C prior to usage. Rituximab and bevacizumab samples were 
adjusted to concentrations of approximately 2 mg/mL (concentrations recorded using a 
NanoDrop One Microvolume Spectrophotometer [ThermoFisher Scientific]) and mixed 
at a 1:1 (v/v) ratio with bodipy maleimide stock solution and incubated overnight at 4°C. 
Samples were then injected onto a Waters Acquity UPLC BEH450 SEC column (1.7µm, 
2.1 x 150mm) at an injection volume of 10µL and isocratically delivered with a mobile 
phase composed of 20% ACN (0.1% TFA)/80% water (0.1% TFA) at a flow rate of 0.3 




nm, emission: 514 nm). Fluorescence AUCs were normalized to concentration and 
compared. 
 Results 
Infliximab vs Rituximab Bevacizumab 
 First, we quantified and compared expected disulfide, shuffled disulfide and 
trisulfide bonds for originator and biosimilar infliximab. The relative contribution of 
expected bonds (relative to sum of expected disulfide, shuffled disulfide and trisulfide 
bonds) and normalized contributions (relative to total expected XIC AUC) of all isolated 
expected bond locations for originator/biosimilar infliximab are shown in Fig. 4-1. The 
relative contribution of expected bonds for originator infliximab (99.579 ± 0.045%) was 
slightly higher than the biosimilar (99.447 ± 0.004%, p < 0.05). When normalized 
contributions were calculated for isolated expected bond locations, no differences were 
observed between the originator and the biosimilar. While variation appears high 
between expected bond locations, ranging between 0.2 and 27.0% normalized 
contribution, a fairly even distribution between expected bond locations was indicative of 
a successful and thorough digestion. 
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Figure 4-1. Comparison of infliximab originator/biosimilar by (A) relative expected contributions and (b) 
normalized contributions; Relative = divided by XIC AUC Totals of expected disulfide, shuffled disulfide 




The relative contribution of shuffled disulfide bonds and the normalized 
contribution of the top ten most prevalent shuffled bond locations for originator and 
biosimilar infliximab are shown in Fig. 4-2.  
The relative contribution of shuffled disulfide bonds for biosimilar infliximab 
(0.546 ± 0.004%) was observed to be higher than the originator (0.418 ± 0.044%, p < 
0.05). When comparing normalized contributions of the top ten shuffled bond locations, 
no significant differences were observed between originator and biosimilar infliximab. In 
addition, indicating that both originator and biosimilar infliximab undergo similar 
mechanisms of degradation. Of the ten listed shuffled disulfide bonds, five occur 
between cysteines in the variable region and five occur between a cysteine in the 
variable region and a cysteine in the constant region. Five of the listed shuffled disulfide 
bonds occur between the HC and LC (inter-chain), while two occur within the LC and 
three occur within the HC (intra-chain). The shuffled locations 194-194 and 214-214 
stood out as examples of a limitation of the described method (see Discussion). 
Figure 4-2. Comparison of shuffled disulfide bonds when trypsin digested at pH 5 for originator/biosimilar 
infliximab by (A) relative shuffled contributions and (B) normalized shuffled contributions for the top 10 




The relative contribution of trisulfide bonds and normalized contributions of the 
only two detected trisulfide bonds are shown in Fig. 4-3. The relative trisulfide 
contribution for originator infliximab (0.002%) was slightly lower than the biosimilar 
(0.006%). Originator/biosimilar infliximab had similar normalized contributions, though 
both were extremely low only appearing mainly at the 134-223 location. 
Next, we quantified and compared expected disulfide, shuffled disulfide and 
trisulfide bonds for originator and biosimilar rituximab. The relative contribution of 
expected bonds (relative to sum of expected disulfide, shuffled disulfide and trisulfide 
bonds) and normalized contributions (relative to total expected XIC AUC) of all isolated 
expected bond locations for originator/biosimilar infliximab are shown in Fig. 4-4. The 
relative contribution of expected bonds for originator infliximab (99.76 ± 0.12%) was 
identical to the biosimilar (99.73 ± 0.04%). When normalized contributions were 
calculated for isolated expected bond locations, no differences were observed between 
the originator and the biosimilar. While variation appears high between expected bond 
locations, ranging between 0.1 and 63% contribution. This large range, in addition to a 
poor distribution between expected bond locations, was indicative of a digestion that 
Figure 4-3. Comparison of trisulfide bonds for originator/biosimilar infliximab (A) relative trisulfide 




was not as thorough, relative to the digestion seen for infliximab expected bond 
locations. 
The relative contribution of shuffled disulfide bonds and the normalized 
contribution of the top ten most prevalent shuffled bond locations for originator and 
biosimilar infliximab are shown in Fig. 4-5. 
The relative contribution of shuffled disulfide bonds for originator rituximab (0.24 
± 0.12%) was also observed to be identical to the biosimilar (0.27 ± 0.04%). When 
comparing normalized contributions of the top ten shuffled bond locations, no significant 
Figure 4-4. Comparison of originator/biosimilar rituximab by (A) relative expected contributions and (b) 
normalized contributions. 





differences were observed between originator and biosimilar infliximab as variation was 
high. No trisulfides were detected for rituximab. 
Next, we quantified and compared expected disulfide, shuffled disulfide and 
trisulfide bonds for originator and biosimilar bevacizumab. The relative contribution of 
expected bonds (relative to sum of expected disulfide, shuffled disulfide and trisulfide 
bonds) and normalized contributions (relative to total expected XIC AUC) of all isolated 
expected bond locations for originator/biosimilar bevacizumab are shown in Fig. 4-6. 
The relative contribution of expected bonds for originator bevacizumab (99.3 ± 0.12%) 
was higher than the biosimilar (98.0 ± 0.35%). When normalized contributions were 
calculated for isolated expected bond locations, two significant were observed that were 
not seen for both infliximab and rituximab, at the 134-194 and 267-327 locations. While 
variation again appears high between expected bond locations, this distribution appears 
to be similar to that seen for rituximab, indicative of a digestion that was not as 
thorough, relative to the digestion seen for infliximab expected bond locations. 
Figure 4-6. Comparison of originator/biosimilar bevacizumab by (A) relative expected contributions and 




The relative contribution of shuffled disulfide bonds and the normalized 
contribution of the top ten most prevalent shuffled bond locations for originator and 
biosimilar bevacizumab are shown in Fig. 4-7. 
The relative contribution of shuffled disulfide bonds for the biosimilar (0.546 ± 
0.004%) was observed to be higher than the originator (0.418 ± 0.044%, p < 0.05) was 
observed to be less than the, p < 0.05). When comparing normalized contributions of 
the top ten shuffled bond locations, significant differences were observed between 
originator and biosimilar infliximab at the 194-373 location (inter-chain). In addition, 
indicating that both originator and biosimilar infliximab undergo similar mechanisms of 
degradation. Of the ten listed shuffled disulfide bonds, five occur between cysteines in 
the variable region and five occur between a cysteine in the variable region and a 
cysteine in the constant region. Nine of the listed shuffled disulfide bonds occur 
between the HC and LC (inter-chain), while one occurs within the HC (intra-chain). 





The relative contribution of trisulfide bonds and normalized contributions of the 
only two detected trisulfide bonds are shown in Fig. 4-8. The relative trisulfide 
contribution for originator infliximab (0.002%) was slightly lower than the biosimilar 
(0.006%). Originator/biosimilar infliximab had similar normalized contributions, though 
both were extremely low only appearing mainly at 22-96, an expected intra-chain bond, 
and 194-226, an inter-chain bond, locations. 
 Bevacizumab and infliximab biosimilars exhibited greater disulfide shuffling and 
trisulfide bonding than their originator counterparts, while rituximab originator and 
biosimilar were identical, where no trisulfide bonds were detected. In addition, we were 
able to rank order the originator and biosimilar pairs, where bevacizumab had the most 
disulfide shuffling and trisulfide bonding while rituximab had the least disulfide shuffling 
and no trisulfide bonds were detected. 
  
Figure 4-8. Comparison of trisulfide bonds for originator/biosimilar bevacizumab (A) relative trisulfide 




 Free thiol content for these originator and biosimilar infliximab, rituximab and 
bevacizumab pairs were determined. Chromatograms for samples labeled with bodipy 
maleimide are shown below in Fig. 4-9 and are quantified in Fig. 4-10. 
  
Figure 4-9. SEC-LC chromatogram overlays of originator/biosimilar (A) infliximab, (B) rituximab and (C) 
bevacizumab when labeled overnight with bodipy maleimide. 
Figure 4-10. Quantified AUCs for SEC-LC chromatogram of originator/biosimilar infliximab, rituximab and 




 The first noticeable difference observed was that observed between SEC-LC 
chromatograms of different mAb types, where originator and biosimilar infliximab, 
rituximab and bevacizumab all exhibited different distribution profiles. All three profiles 
have what appears to be a main peak at retention times between 3.6 and 3.9 minutes 
with significant tailing. While bevacizumab only has a minor secondary peak at  
approximately 3.4 minutes, infliximab has a noticeably larger secondary peak at 2.9 
minutes while infliximab has a secondary peak at approximately 3.1 minutes. While 
profile distributions may seem of interest, understanding of contributing peaks is 
rendered less useful due to the use of 20% ACN organic phase in the mobile phase. 
Therefore, AUC was quantified and compared totals between approximately 2 and 6 
minute retention times, where AUCs were representative of free thiol content. 
 We first compared originators against biosimilars, where we observed more thiol 
content for biosimilar infliximab and bevacizumab than their originators. For rituximab, 
though, the originator had a more free thiols than the biosimilar. In addition, rituximab 
had the most free thiols. In relations to disulfide shuffling, the biosimilar for both 
infliximab and bevacizumab exhibited greater disulfide shuffling and trisulfide bonding, 
seemingly indicating a relationship between free thiol content and disulfide shuffling. For 
rituximab, though, the originator had more free thiols while disulfide shuffling was similar 
for both. Unlike the other two mAb, this would seem to indicate that there is no 
relationship between free thiols and disulfide shuffling. This would likely be explained by 
the fact that the free thiol assay is limited by when free thiols are detected. For 
rituximab, newly exposed free thiols seem to be detected while free thiols for 




Originator/Biosimilar Rituximab and Bevacizumab Subject to Forced Degradation 
Electrophoresis Gels 
 Gels were run at concentrations of 0.25 and 0.4 mg/mL to visualize the presence 
of minor aggregate and fragment component bands (Fig. 4-11).  
The main monomer bands appear at a MW of approximately 145 and 150 kD, 
which matches the expected MWs reported in package inserts as 145 and 149 kD, 
respectively.441,442 While difficult to precisely quantify due to band overlap, there are 
some observed trends observed where the originator/biosimilar mAb pairs differed over 
the course of incubation. When comparing rituximab originator/biosimilar, we noticed 
that initial amounts of aggregates (~155 kD) and fragments (~115 kD) were present that 
did not seem to change over the course of incubation. In terms of differences observed, 
the rituximab biosimilar had distinct initial aggregates (~255 kD, not present in the 
originator) that did not appear to change over the course of incubation. The innovator’s 
85 kD fragment does appear to increase over the course of incubation, but only after 4 
weeks. Bevacizumab originator and biosimilar appeared similar in terms of levels of 
aggregates and fragments both initially and over the course of incubation. In terms of all 
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Figure 4-11. SDS PAGE gels for bevacizumab and rituximab originator and biosimilar mAb pairs at (A) 
0.25 and (B) 0.4 mg/mL comparing HiMark Prestained Protein Ladder against mAb pairs after 0, 2 and 4 




mAbs, a small fragment component at ~41 kD was present at 0.4 mg/mL and seemed to 
be the most intense after 4 weeks of incubation. On the whole, it appears that our 
rituximab and bevacizumab originator/biosimilar pairs to start with initial degradant 
components that also changed over the course of incubation. It is of note that these 
studies were performed on expired mAb products. The relative contribution from 
aggregate, monomer and fragment species were quantified and shown in Fig. 4-12.  
SEC Physical Degradation Analysis 
 Physical degradation of bevacizumab and rituximab originator/biosimilar pairs 
were also compared by SEC over the course of incubation and were quantified as a 
function of change of levels of monomer and degradants, including aggregates and 
fragments SEC-LC chromatograms are shown below in Fig. 4-13 and are quantified in 
Fig. 4-14, where marked differences were observed both initially and over the course of 
incubation. The samples analyzed were the same as those that run on SDS-PAGE gels. 
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Figure 4-12. SDS-PAGE relative contributions for rituximab originator/biosimilar (A) aggregates, (B) 
monomer and (C) fragments and relative contributions for bevacizumab originator/biosimilar (D) 




The purpose was to investigate if similar trends of degradation were observable by 
orthogonal methods prior to analysis by LC-MS/MS, the main focus of this chapter. 
A C E G
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Figure 4-13. SEC-LC chromatograms of rituximab originator at (A) 0 and (B) 4 and biosimilar at (C) 0 and 
(D) 4 weeks of incubation at 37ºC. Bevacizumab originator at (E) 0 and (F) 4 and biosimilar at (G) 0 and 
(H) 4 weeks of incubation at 37ºC. 
Figure 4-14. SEC relative contributions for rituximab originator/biosimilar (A) aggregates, (B) monomer 
and (C) fragments and relative contributions for bevacizumab originator/biosimilar (D) aggregates, (E) 




The rituximab originator was observed to have the most amount of initial 
monomer content (94.4%), least amount of initial degradants, which included mainly 
fragments (5.2%) and small amounts of aggregates (0.3%). Rituximab did not exhibit 
monomer loss over incubation. Lower levels of initial monomer content (94.0%) were 
observed for the rituximab biosimilar (94.0%), which reflected an elevated level of 
aggregates (0.9%), while levels of fragments were similar (5.2%). Unlike rituximab 
originator, the biosimilar exhibited a decrease in monomer content over incubation, with 
increases of fragments (to 6.1%) and aggregates (to 1.1%) after 4 weeks. 4-week 
originator/biosimilar rituximab/bevacizumab chromatograms qualitatively show 
observable differences for the relative contribution of aggregates and fragments. 
While the bevacizumab originator had similar initial levels of monomer content 
(94.3%) as the rituximab originator, there were relatively more aggregates (1.3%) for 
bevacizumab. Again, the main degradant species were fragments. The bevacizumab 
biosimilar had the least initial monomer content (92.9%). While having the most relative 
amounts of aggregates, fragments were the main degradant observed. Both 
bevacizumab originator/biosimilar degraded to a greater extent than rituximab 
originator/biosimilar, with monomer content decreasing to 91.6% to 90.6% over 
incubation, respectively. While fragments make up the largest relative degradant 
species, further bevacizumab originator degradation, increasing to 3.85% over 
incubation. Degradation of bevacizumab biosimilar appeared to be driven by both 
aggregation, increasing to 4.09%, and fragmentation, increasing to 5.37%, after 4 





Disulfide Bond Analysis: Expected vs Shuffled vs Trisulfide 
 Expected disulfide bond locations for rituximab and bevacizumab are shown 
below in Fig. 4-15. Upon inspection of their amino acid sequences, expected disulfide 
bond locations and number of cysteines (32, the minimum number required for 
expected bonds) were confirmed to be similar, as is expected for IgG1 mAbs.  
Figures were generated from Protein Metrics Byonic/Byologic workflow, where mAbs 
were compared as a function of quantifiable XIC AUCs. Relative contributions of 
expected disulfide, shuffled disulfide and trisulfide bonds, when detected, for originator 
and biosimilar rituximab and bevacizumab pairs over the course of incubation are 











   
As shown previously, the initial relative contribution from expected and shuffled 
disulfide bonds for rituximab originator and biosimilar were similar, where no trisulfide 
bonds were detected. Minor decreases of expected disulfide bonds were matched by 
similar increases of shuffled disulfide bonds for the originator (to 0.28 ± 0.02 and 0.51 ± 
0.06%) and biosimilar (to 0.38 ± 0.09 and 0.35 ± 0.05%) after 2 and 4 weeks of 
incubation, respectively. The relative contributions and trends of changes of expected 
bonds seem to support the trends observed for physical degradation analyzed by SEC 
and SDS-PAGE, where rituximab originator and biosimilar appeared to undergo less 
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Figure 4-16. Relative contributions of expected disulfide bonds, shuffled disulfide bonds and trisulfide 
bonds for (A) rituximab originator/biosimilar and (B) bevacizumab originator/biosimilar over the course of 




degradation over incubation than bevacizumab. Both the originator and biosimilar have 
increases of disulfide shuffling over the incubation. 
For bevacizumab, the initial relative contribution from expected disulfide bonds 
was observed to be greater for the originator than the biosimilar. This difference which 
was matched by greater amounts of shuffled and trisulfide disulfide bonds for the 
biosimilar than the originator (1.62 ± 0.45 and 0.37 ± 0.11%). In addition, the trends of 
degradation by disulfide bond analysis appeared different over the incubation. Whereas 
the trend of degradation for the originator appears normal, where a decrease of relative 
expected contribution (to 98.8 ± 0.45 and 97.91 ± 0.35%) is matched by an increase of 
relative shuffled contribution (to 1.09 ± 0.35 and 1.46 ± 0.64%) and increase of relative 
trisulfide contribution (to 0.14 ± 0.10 and 0.62 ± 0.37%) after 2 and 4 weeks, 
respectively. The trend of degradation for the biosimilar appears to be inverse, where 
the initial time point is the most degraded with a a decrease of relative shuffled 
contribution (to 1.09 ± 0.35 and 1.46 ± 0.64%) and a decrease of relative trisulfide 
contribution (to 0.31 ± 0.04 and 0.12 ± 0.03%) after 2 and 4 weeks, respectively. While 
unusual, these results appear to match physical degradation results when analyzed by 
SEC and SDS-PAGE, where bevacizumab initially has more degradants, though the 
relationship between the two becomes muddled over incubation, where loss of shuffled 






 Distributions and locations of shuffled bonds were identified and compared for 
rituximab and bevacizumab originator/biosimilar over the course of incubation and are 
reported as normalized contributions to shuffled XIC AUC totals (Fig. 4-17). Shuffled 
bond locations were organized as a function of inter-chain and intra-chain bonds. Intra-
chain bonds were observed to make up the clear minority of shuffled bonds for both 
rituximab (133-224 and 230-429) and bevacizumab (22-88 and 96-226). It should also 
be noted that the digestion again appears incomplete as sample-to-sample variations 







Figure 4-17. Normalized contributions of shuffled bonds comparing originator/biosimilar rituximab at (A) 0, 
(B) 2 and (C) 4 weeks and bevacizumab at (D) 0, (E) 2 and (F) 4 weeks of incubation at 37°C; n = 3, 




For rituximab, there were no significant differences detected between the 
originator/biosimilar at all time points. In addition, shuffled bond distributions for 
rituximab remained somewhat similar over the course of incubation. Though not 
statistically significant, a general trend of similarity was indicated by the normalized 
contribution of the largest 2 shuffled bond species at 96-224 and 133-148 locations for 
the originator and biosimilar at, 63.4 ± 55.1% and 82.9 ± 28.0, 92.6 ± 10.9% and 88.2 ± 
17.1% and 4 86.8 ± 22.0% and 87.4 ± 9.4% at 0, 2 and 4 weeks, respectively. These 
two shuffled bond locations were the only ones detected across all 3 samples. 
 For bevacizumab, there was only 1 observed statistically significant difference at 
the 194-373 location, which made up 88.6 ± 6.8% (originator) and 49.3 ± 20.4% 
(biosimilar) at 0 weeks (p < 0.01). Though no statistically significant differences were 
observed at 2 weeks, the most significant differences were observed at 4 weeks at the 
following shuffled bond location; 194-327, 0.9 ± 1.6% vs 42.2 ± 7.3% (p < 0.001), 194-
373, 18.1 ± 15.8% vs 45.4 ± 8.1% (p < 0.005), and 214-206, 81.0 ± 16.5 % vs 0% (p < 
0.001). Trends in shifts of distributions of shuffled disulfide bonds are specifically 
indicated through the 194-373 location, which makes up 88.6 ± 11.8% and 49.3 ± 
35.3%, 51.5 ± 43.0% and 67.1 ± 23.9% and 18.1 ± 15.8% and 45.4 ± 8.1.% for the 
originator and biosimilar at 0, 2 and 4 weeks, respectively. This single location is the 
only location detected across all three samples. The shift in distribution of shuffled 
bonds for bevacizumab indicates not only that there is a difference between 
bevacizumab originator/biosimilar, but also that bevacizumab degraded more 




 Trisulfide bonds were only identified in bevacizumab. Trisulfide bond distributions 
were compared between bevacizumab originator/biosimilar over the course of 
incubation and are shown as normalized contributions to trisulfide XIC AUC totals (Fig. 
4-18). Trisulfide bond locations were observed at expected, inter-chain and intra-chain 
locations. The majority of trisulfide bonds were observed as a subset of the 22-96 
(expected) and 194-226 (shuffled) bond locations. Distributions were observed to shift 
over the course of incubation, which, unlike rituximab matches the increased 








Figure 4-18. Normalized trisulfide contributions for bevacizumab at (A) 0, (B) 2 and (C) 4 weeks of 




Free Thiol Analysis: Maleimide 
 Bodipy maleimide was used to investigate the potential relationship of free thiols 
to physical degradation and disulfide shuffling. Bodipy maleimide is a free thiol probe, 
where conjugation allows for detection by fluorescence. Free thiols were compared as a 
function of total AUC as organic is used in the mobile phase. The main assumption for 
this method was that a higher AUC is an indicator of larger amounts of free thiols. 
Samples were the same as those previously characterized by SDS PAGE and SEC. 
Fluorescence SEC-LC chromatograms for bodipy maleimide labeled originator rituximab 
and bevacizumab samples over the course of incubation are shown in Fig. 4-19 and are 





Figure 4-19. Fluorescence SEC-LC chromatograms overlays of OR/BS at 0,2 and 4 weeks of incubation 




For both rituximab and bevacizumab, the unlabeled blanks appeared at a 
retention time of approximately 4 minutes (data not shown). While a similar retention 
time appears for mAb samples labeled with bodipy maleimide, rituximab exhibits the 
formation of a secondary species at a retention time of approximately 3.1 minutes, while 
bevacizumab shows a small secondary peak at approximately 3.4 minutes. In addition, 
the main component for both appears to have significant tailing starting at approximately 
4.05 minutes. A current limitation of this technique arises due to the use of organic 
phase ACN, which muddles our ability to differentiate the identity of each individual 
component in such chromatograms, hence why total AUCs are compared, as shown in 
Fig. 4-20. 
 Changes of AUCs for originator/biosimilar rituximab/bevacizumab were 
compared over the course of incubation. Relative to 0 weeks, the rituximab originator 
AUC was 29.9 and 10.1% higher at 2 and 4 weeks, respectively. The AUC for the 
biosimilar, while initially less than the originator, increased approximately 24.4 and 
Figure 4-20. Free thiol total fluorescence AUCs for rituximab and bevacizumab OR/BS at 0, 2 and 4 




120.8% after 2 and 4 weeks of incubation, respectively. Relative to the rituximab 
originator made up for 67.7% and 64.9% of total AUC at 0 and 2 weeks, respectively. At 
4 weeks, though the biosimilar AUC was 35.9% higher than the originator. While 
disulfide shuffling was similar, increasing over the incubation, physical degradation was 
also the greatest for the biosimilar after 4 weeks of incubation. 
Relative to 0 weeks, AUC for the bevacizumab originator increased by 4.9 and 
14.1%, while the biosimilar increased similarly by 2.6 and 14.4% after 2 and 4 weeks of 
incubation, respectively. When comparing the AUC of the biosimilar against the 
originator, a consistent trend emerged, whereby the biosimilar was relatively higher than 
the originator at by 6.1%, 3.7% and 6.3% at 0, 2 and 4 weeks, respectively. This trend 
would make sense in conjunction with results seen for physical degradation and 
disulfide shuffling, where the biosimilar was more prone to aggregation and disulfide 
shuffling than the originator, though both were more prone to degradation than 
rituximab. In addition, free thiols for rituximab ranged between 2- and 3-fold higher than 
the bevacizumab samples at all time points. Again, the trend of less amounts of free 
thiols for bevacizumab would seem to be related to the fact that they are already 
participating in disulfide shuffling and aggregation, whereas newly exposed free thiols 





Disulfide Analysis of Infliximab, Rituximab and Bevacizumab Pairs 
 The relative contribution of expected disulfide bonds was found to be significantly 
lower for biosimilar infliximab and bevacizumab than their originator, with both having 
greater disulfide shuffling and trisulfide bonding. While there were no significant 
differences observed when comparing the normalized contributions of isolated expected 
bond locations between originator and biosimilar infliximab, there were significant 
differences detected between originator and biosimilar bevacizumab. It is important to 
note the variation of normalized contributions across expected bond locations, with 
values ranging over two orders of magnitude. This variation is inherent to the LC-
MS/MS method and is attributed to differences between ionization efficiencies of 
peptide sequences as one sequence may not “fly” similarly to another.443 Therefore, 
further probing into the values of the distribution of expected bond locations should be 
taken into consideration, especially when evaluating if the digestion was complete and 
thorough. Relative to infliximab, the normalized expected contributions from rituximab 
and bevacizumab would imply their digestions were not complete and thorough. Even 
so, this variability is resolved by focusing on the comparability between the originator 
and biosimilar. While the top ten most prevalent shuffled locations were identical for 
originator and biosimilar infliximab and rituximab, indicating similarity of degradation 
pathways, they were not similar for originator and biosimilar bevacizumab. In terms of 
trisulfide bonding, there were only two trisulfide bonds detected at very low amounts for 
infliximab (less than 0.01%), while trisulfide bonding was markedly higher for the 




and biosimilar had the least amount of disulfide shuffling and no trisulfide bonding. 
Originator and biosimilar infliximab had slightly more disulfide shuffling and trisulfide 
bonding, while originator and biosimilar bevacizumab had the most disulfide shuffling 
and trisulfide bonding. 
Intramolecular vs Intermolecular Disulfide Shuffling 
Another concept that must be accounted for is the difference of disulfide shuffling 
that occurs within a molecule (intra-molecular) and disulfide shuffling that occurs 
between two different molecules (inter-molecular). This is exemplified by the 194-194 
and 214-214 shuffled bond locations (Fig. 4-2), which require intermolecular bonding. 
The addition of an orthogonal technique with high resolution of minimally present and 
intact degraded/shuffled species would be useful. 
Effect of Forced Degradation on Rituximab and Bevacizumab Pairs 
Disulfide Bond Analysis 
Though trends of decrease of relative expected contribution were observed for 
both originator and biosimilar rituximab, decreases were only slight and matched by 
increases of disulfide shuffling. No trisulfide bonds were detected for rituximab. Relative 
to rituximab, though originator and biosimilar bevacizumab had markedly reduced 
relative expected contributions and increased amounts of disulfide shuffling and 
trisulfide bonding. Within rituximab, the originator and biosimilar were similar, increasing 
over the incubation. Within bevacizumab, though the biosimilar had the largest amount 
of shuffling and trisulfide bonding at 0 weeks, which decreased after 2 and 4 weeks of 




disulfide shuffling and trisulfide bonding. Even with the observed trends, changes of 
disulfide shuffling and trisulfide bonding were not statistically significant. 
Normalized contributions of shuffled disulfide and trisulfide bond locations were 
then compared. Disulfide bonds for originator and biosimilar rituximab, indicated by 
similar distribution profiles of disulfide bond locations. were similar both initially and over 
the course of incubation, indicating that forced degradation did not cause the formation 
of differences. This was not the case for bevacizumab. In addition to significant initial 
differences in terms of disulfide bond locations, these initial differences appear to be 
exacerbated by incubation, with distributions becoming even more different after 4 
weeks of incubation. This shift in distribution is a key indicator that bevacizumab seems 
to be not only more prone to degradation both the originator and biosimilar rituximab, 
but also a difference in degradation between the originator and biosimilar bevacizumab. 
A similar trend for normalized trisulfide contributions was observed as that seen for 
disulfide bonds, having both initial differences that  were exacerbated over incubation. 
Relationship Between Physical Degradation, Disulfide Shuffling and Free Thiols 
 Common orthogonal physical characterization techniques were implemented to 
understand the potential relationship of physical degradants with disulfide shuffling. 
Similar trends in terms of the relative contributions from aggregate, monomer and 
fragment species were observed by both SDS-PAGE and SEC-LC. Originator and 
biosimilar rituximab remained similar over the course of incubation, though the 
biosimilar was slightly more degraded. On the other hand, originator and biosimilar 
bevacizumab were more initially degraded. Where differences were exacerbated  with 




bevacizumab. The routes of physical degradation of rituximab and bevacizumab 
appeared to differ, where rituximab degradation was characterized mainly by the 
presence (and increase) of fragments while bevacizumab  degradation was 
characterized by the increase of aggregates and fragments. The trends of increases of 
shuffled and trisulfide bonding for both seemed to match the degree and rate of physical 
degradation observed by these techniques. 
 The method developed for free thiol analysis was a result of several unsuccessful 
attempts using several previous approaches that are often used to determine free thiols. 
The first method tested was with Ellman’s reagent, which was only applied to 
bevacizumab. We were unable to observe any free thiols, which may imply that 
bevacizumab does not have enough free thiols to appropriately reach the limit of 
detection. We then tried a technique found in a previously published paper, whereby the 
authors tested conjugation of various maleimide reagents with analysis by RPLC and 
UV detection.158 Results using that method differed vastly from those reported (data not 
shown). We then found bodipy maleimide that imparts fluorescence and adjusted a 
common SEC method (that used 1x PBS as a mobile phase) by introducing 20% ACN 
to the mobile phase, the upper limit for our specified column. As far as we are aware, 
this bodipy maleimide method is not currently found in the literature for this application. 
 There are 2 potential underlying hypotheses that influence how free thiol data 
may be understood. The first hypothesis is that a greater amount of free thiols may 
induce degradation; the second hypothesis is that free thiol content increases as mAbs 




mAbs subjected to force degradation, one must consider types of physical degradants 
that may form.  
 To address the first hypothesis, where increased initial free thiol content could 
result in increased degradation, we notice that rituximab originator/biosimilar have 
approximately twice the AUC relative to bevacizumab. These results do not support 
such a hypothesis as rituximab undergoes less physical degradation and disulfide 
shuffling. On the other hand, the bevacizumab biosimilar was observed to have higher 
free thiol AUC at all time points relative to the originator and exhibited increased 
physical degradation and disulfide shuffling. In combination, these would seem to 
indicate that we can only compare initial free thiol content between an originator and a 
biosimilar. To address the second hypothesis, higher free thiol content was observed 
over the course of incubation for all mAb samples. Free thiol increases that were 
observed for rituximab originator/biosimilar were markedly higher than for bevacizumab. 
Additionally, increases for the rituximab biosimilar were higher than the originator, while 
increases for bevacizumab originator/biosimilar were approximately the same. This 
would seem to support such a hypothesis, though direct comparison between 
originator/biosimilar becomes more complex. Further studies would be necessary to 
elucidate whether the proposed hypothesis is valid. 
Our results seem to indicate a limitation of our assay, where we are unable to 
determine when free thiols are detected. It appears that for rituximab, newly exposed 
free thiols are detected, hence a large increase. For bevacizumab, free thiols are 
detected after participating in disulfide shuffling and physical degradation, hence the low 





Chapter 5: Conclusions and Future Directions 
The work presented in this thesis focuses on aspects related to the development 
of peptide and mAb biopharmaceutical products. Via forced degradation, a combination 
of state-of-the-art and orthogonal characterization techniques provide valuable and 
comprehensive information on various instability mechanisms of biopharmaceutical 
products.  
The first chapter provides a general introduction on the state of approval of 
biopharmaceutical products and their generic/biosimilar versions, analytical 
methodologies used to prove biosimilarity and typical instability mechanisms observed 
during forced-degradation studies of peptide and protein products. In the second 
chapter, we investigated the long-term stability of exenatide, a 39 amino acid GLP-1 
receptor agonist peptide that is used to treat type 2 diabetes. While patent expirations 
for exenatide products are looming, novel extended-release formulation of GLP-1 
agonists and recent co-formulations with insulin analogs warranted investigation of 
exenatide’s stability profile as a representation of potential GLP-1 agonist degradation 
mechanisms. In addition, a recent focus on the effect of peptide degradants on 
immunogenic responses is a critical regulatory consideration for the approval of generic 
versions of exenatide as well as novel sustained-released formulations of peptide. 
When exenatide was studied at elevated pH, rapid chemical and physical degradation 




deamidation impurities while physical degradation was mainly attributed to dimerization, 
aggregation and loss of α-helicity, which was matched by an increase of unordered 
structural content. Aggregation was proposed to be a function of Trp-cage disruption. 
The addition of common excipients to the peptide solution, despite some of their 
presumed protective functions, were unable to prevent degradation at elevated pH 7.5. 
In fact, trehalose seemed to further destabilize exenatide. While a previous publication 
has investigated the impact of deamidation chemical impurities on GLP-1R binding, we 
observed the formation of multiple additional oxidation chemical impurities, that had yet 
to be characterized for their biological activities. In addition, while we do see the 
formation of multiple oxidation and deamidation impurities, we are unsure of the 
locations of the modified amino acid residues. There are three sets of future studies that 
may be applicable as a follow-up. The first, detailed identification of the locations of 
chemical modifications on exenatide’s sequence and understanding of how individual 
modifications impact a GLP-1R receptor binding. The second study could be focused on 
development of an understanding of how chemical and physical impurities of exenatide 
impact peptide immunogenicity. This study will be critical for the approval of generic 
version of Byetta and Bydureon. The third set of future studies, though not of exenatide 
itself, would be the generation of stability profiles of currently marketed GLP-1R/insulin 
analog co-formulations (Xultophy and Soliqua). 
In the third and fourth chapters, comparability studies of originator/biosimilar 
infliximab, rituximab and bevacizumab pairs were performed. In both chapters, we 
investigated the applicability of tandem mass spectrometry (LC-MS/MS) to elucidate 




methods like gel electrophoresis (SDS-page) and size exclusion chromatography 
(SEC).  We also investigated whether initial purity differences between originator and 
biosimilar pairs would be amplified over the course of forced degradation studies to 
provide additional information on the biosimilarity of different products.  
In the third chapter, minor differences between infliximab originator and biosimilar 
were found over the course of incubation, including differences of heat capacity, intrinsic 
fluorescence, subvisible particulates, deamidation tendencies and fragmentation levels, 
though these differences were not determined to be statistically significant between 
originator and biosimilar products. Degradation mechanisms and kinetics were found to 
be highly similar.  
In the first part of the fourth chapter, tandem mass spectrometry (LC-MS/MS) 
was used to compare disulfide bonding for an originator/biosimilar infliximab, rituximab 
and bevacizumab pairs, where LC-MS/MS outputs were analyzed using a Protein 
Metrics’ Byonic™ and Byologic® workflow, which allowed for the detection, identification, 
quantification and comparison of expected disulfide bonds and related impurities 
(shuffled disulfide and trisulfide bonds). The relative contribution of shuffled and 
trisulfide bonds were found to be higher for biosimilar infliximab and biosimilar 
bevacizumab than their respective originators. On the other hand, for rituximab, the 
relative contribution of shuffling for the biosimilar was identical to that seen for originator 
and no trisulfides were detected. These differences of disulfide shuffling would seem to 





In the second part of the fourth chapter, originator and biosimilar rituximab and 
bevacizumab were subject to forced degradation, where these pairs were incubated at 
37ºC for 4 weeks at. LC-MS/MS was used to compare changes of shuffled disulfide and 
trisulfide bonds over the course of incubation. The relative contribution of shuffled 
disulfide bonds for originator/biosimilar rituximab were similar over the course of 
incubation. The relative contribution of disulfide shuffling for originator and biosimilar 
bevacizumab not only started with higher initial levels of disulfide shuffling and trisulfide 
bonding but also had greater extents of shuffling over incubation. In addition, the 
relative contribution of disulfide shuffling for biosimilar bevacizumab was greater than 
the originator. Physical degradant characterization (SDS PAGE and SEC) was then 
used to assess and confirm the relationship of protein degradation to disulfide shuffling. 
It was observed that bevacizumab was more prone to both physical degradation and 
disulfide shuffling than rituximab, where again the biosimilar bevacizumab had more 
initial degradation than the originator. Lastly, free thiol content was analyzed. Free thiol, 
while appearing greater for rituximab than bevacizumab, appeared to be related to less 
disulfide shuffling and less physical degradation, whereby free thiols were detected 
upon exposure over incubation. For bevacizumab, free thiol content also appeared 
related. Though less free thiols were detected, this is likely due to their participation in 
disulfide shuffling and degradation that was greater than that observed for rituximab. 
Current limitations of the fourth chapter include a lack of understanding of intra- 
versus inter-molecular disulfide shuffling, as exhibited by 194-194 and 214-214 shuffled 
bond location for originator/biosimilar infliximab. This could be accounted for by a 




understand the percentage of these aggregates that are covalent by nature. Further 
studies could also include investigation between discrepancies resulting from the high 
variability of trypsin digestion that were seen between the two sections of this chapter. 
Normalized expected, shuffled and trisulfide bonds contributions appeared more evenly 
distributed than those detected for rituximab and bevacizumab samples, where large 
variabilities occur likely as a result of an incomplete digestion, exemplified the two 
shuffled locations that were expressed for all three samples of rituximab originator and 
biosimilar.  
Other future studies potentially lie in the understanding of the free thiol analysis 
method that we have developed using bodipy maleimide as a free thiol probe. Current 
literature on this method is lacking. In addition, further identification of contributing 
peaks (determined by SEC fluorescence) would prove useful. Lastly, the generation and 
generation of large numbers of aggregate and fragment species, followed by 
fractionation, would additionally allow for us to determine the relative contributions from 
mAb fragments and aggregates. Further investigation of the underlying mechanisms of 
disulfide shuffling as a function of free thiol content is also warranted.  
Additionally, analysis of disulfide shuffling, in combination with orthogonal 
physical degradation characterization techniques can be applied to any protein 
containing two or more disulfide bonds. As an example, this could be applied to insulin 
analogs. Although fibrillation of insulin analogs has been studied, the role of disulfide 





Overall, each of these projects is useful to companies seeking regulatory 
approval for a wide variety of biotherapeutic products. The second chapter applies 
specifically to development of generic and novel delivery technologies of GLP-1RAs, 
which have recently included the advent of co-formulation with long-acting insulin 
analogs (Fig. 5-1). The third chapter applies to any and all future biotherapeutic 
products while the fourth chapter applies to all future biotherapeutic products that 
contain two or more disulfide bonds. 
While information derived from analytical characterization is useful within the 
regulatory space, it provides a backdrop for the continued desirability to correlate 
specific impurities with immunogenic responses, a focus of big pharma. The more 
information that is known about chemical and physical impurities, the more likely we are 
to find these correlations. To do so, investigation of mAbs that have died in clinical 
testing may prove useful to optimizing biopharmaceutical product development and 
approval. While immunogenicity has relied upon the formation of ADAs through 




adaptive immune response, there has been a shift in focus towards innate immune 
responses, which occur upstream of ADA formation (Fig. 5-2).  
Figure 5-2 Hypothesis of TD mechanism of ADA formation by aggregates. (1) Early stage: activated 
APCs stimulate naïve T-cells through interactions of MHC-II and costimulatory molecules (presented on 
the surface of activated APCs) with TCRs and CD28 (presented on T-cells), respectively, turning them 
into activated T-cells. (2) Late-stage: activated T cells differentiate into cytokine secreting T helper cells 
type 2 (Th2). Both antigen binding to BCRs (IgM or IgD) and costimulation of B-cells with antigen-specific 
Th2 cells are required to activate naïve B-cells in the T-cell-rich zones of the secondary lymphoid tissues 
into B2-cells. Mature B2-cells develop oligoclonal monoreactive GCs in the B-cell follicles, in which B-
cells undergo site-directed hypermutation in the Ig variable domain and clonal expansion. Finally, B-cells 
proliferate and differentiate into memory and antibody-secreting plasma cells. The response also involves 
antibody isotype class switching, in which the Ig class is switched (i.e., from IgM or IgD to IgG, IgE, or 
IgA) by alternatively splicing the Ig heavy chain in the constant region. Green rectangles denote stages at 
which studies have evaluated the potential immunogenicity of protein aggregates. BCR = B-cell 
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